<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="pmc-domain-id">1765</journal-id><journal-id journal-id-type="pmc-domain">hvi</journal-id><journal-title-group><journal-title>Human Vaccines &amp; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &amp; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8204314</article-id><article-id pub-id-type="pmcid-ver">PMC8204314.2</article-id><article-id pub-id-type="pmcaid">8204314</article-id><article-id pub-id-type="pmcaiid">8437495</article-id><article-id pub-id-type="pmid">34114940</article-id><article-id pub-id-type="doi">10.1080/21645515.2021.1935172</article-id><article-id pub-id-type="publisher-id">1935172</article-id><article-version-alternatives><article-version article-version-type="pmc-version">2</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2</article-title><alt-title alt-title-type="left-running-head">W. ALTURAIKI ET AL.</alt-title><alt-title alt-title-type="right-running-head">HUMAN VACCINES &amp; IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Alturaiki</surname><given-names initials="W">Wael</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mubarak</surname><given-names initials="A">Ayman</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Al Jurayyan</surname><given-names initials="A">Abduallah</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5986-7237</contrib-id><name name-style="western"><surname>Hemida</surname><given-names initials="MG">Maged Gomaa</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref><xref rid="an0001" ref-type="corresp"/><xref rid="an0002" ref-type="author-notes">
<sup>*</sup>
</xref></contrib><aff id="aff0001"><label>a</label>Department of Medical Laboratory Sciences, College of Applied Medical Sciences, <institution-wrap><institution>Majmaah University</institution></institution-wrap>, <city>Majmaah</city>, <country>Saudi Arabia</country></aff><aff id="aff0002"><label>b</label>Department of Botany and Microbiology, College of Science, <institution-wrap><institution>King Saud University</institution></institution-wrap>, <city>Riyadh</city>, <country>Saudi Arabia</country></aff><aff id="aff0003"><label>c</label>Immunology and HLA Department, Pathology and Laboratory Medicine, <institution-wrap><institution>King Fahad Medical City</institution></institution-wrap>, <city>Riyadh, Al-Ahsa</city>, <country>Saudi Arabia</country></aff><aff id="aff0004"><label>d</label>Department of Microbiology, College of Veterinary Medicine, <institution-wrap><institution>King Faisal University</institution></institution-wrap>, <country>Saudi Arabia</country></aff><aff id="aff0005"><label>e</label>Department of Virology, Faculty of Veterinary Medicine, <institution-wrap><institution>Kafrelsheikh University</institution></institution-wrap>, <city>Kafr Ash Shaykh</city>, <country>Egypt</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Maged Gomaa Hemida <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:mhemida@kfu.edu.sa">mhemida@kfu.edu.sa</email> Department of Microbiology, College of Veterinary Medicine, King Faisal University, Al-Hufuf, Al-Ahsa, Saudi Arabia Po box; 400</corresp><fn id="an0002"><label>*</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>11</day><month>6</month><year>2021</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2021</year></pub-date><volume>17</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">390000</issue-id><fpage seq="8">3297</fpage><lpage>3309</lpage><pub-history><event event-type="pmc-release"><date><day>11</day><month>06</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>16</day><month>06</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-02-08 19:25:13.677"><day>08</day><month>02</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">8204314</article-id><article-id pub-id-type="doi">10.1080/21645515.2021.1935172</article-id><article-version>1</article-version><pub-date><day>11</day><month>06</month><year>2021</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">8437495</article-id><article-id pub-id-type="doi">10.1080/21645515.2021.1935172</article-id><article-version>2</article-version><pub-date><day>11</day><month>06</month><year>2021</year></pub-date></event><event event-type="tagger"><event-desc>Integra</event-desc><date><day>27</day><month>8</month><year>2021</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>27</day><month>8</month><year>2021</year></date></event><event event-type="received"><date><day>31</day><month>3</month><year>2021</year></date></event><event event-type="revised"><date><day>03</day><month>5</month><year>2021</year></date></event><event event-type="accepted"><date><day>24</day><month>5</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Taylor &amp; Francis Group, LLC</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Taylor &amp; Francis</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="KHVI_17_1935172.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="KHVI_17_1935172.pdf"/><abstract><title>ABSTRACT</title><p>SARS-CoV2 infection induces various degrees of infections ranging from asymptomatic to severe cases and death. Virus/host interplay contributes substantially to these outcomes. This highlights the potential roles of the host immune system in fighting virus infections. SARS-CoV-2. We highlighted the potential roles of host immune response in the modulation of the outcomes of SARS-CoV infections. The newly emerged SARS-CoV-2 mutants complicated the control and mitigation strategies measures. We are highlighting the current progress of some already deployed vaccines worldwide as well as those still in the pipelines. Recent studies from the large ongoing global vaccination campaign are showing promising results in reducing the hospitality rates as well as the number of severe SARS-CoV-2 infected patients. Careful monitoring of the genetic changes of the virus should be practiced. This is to prepare some highly sensitive diagnostic assays as well as to prepare some homologous vaccines matching the circulating strains in the future.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>immune response</kwd><kwd>innate immunity</kwd><kwd>adaptive immunity</kwd><kwd>immune evasion</kwd><kwd>escape mutation</kwd><kwd>vaccines</kwd></kwd-group><counts><fig-count count="1"/><table-count count="2"/><ref-count count="121"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><title>Introduction</title><p>The coronavirus infectious disease-19 (COVID-19) is a newly emerged coronavirus discovered in late 2019<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup>. The etiology of this syndrome is severe acute respiratory syndrome-2 (SARS-CoV-2).<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup> The WHO declared that SARS-CoV-2 is the causative agent of the recent modern pandemic across the globe on March 11th, 2020.<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup> SARS-CoV-2 belongs to the subgenus Sarbecovirus, subfamily-<italic toggle="yes">Orthocoronavirinae</italic> within the family <italic toggle="yes">Coronaviridae</italic>, and the order <italic toggle="yes">Nidovirales</italic>. This is the seventh identified human coronavirus. The genome structure and organization of SARS-CoV is very much similar to other coronaviruses, belongs to the Betacoroanviruses along with some other important zoonotic coronaviruses (MERS-CoV and the SARS-CoV). However, the genome sequencing analysis revealed some variation among those viruses across their genomes, particularly the spike glycoprotein (S). The virus genome is a linear single-strand RNA molecule (~ 30-kilobases) in length. The 5&#697;two-third of the viral genome encodes the non-structural proteins, which are responsible for replication and pathogenesis, immune evasion properties of viruses. While, the 3&#697; third of the viral genome encodes four essential proteins (spike glycoprotein (S), the envelope, the membrane (M), and the nucleocapsid proteins (N)) interspersed by some minor non-structural proteins. Some of these proteins play essential roles in the virus replication cycle, immune response, and immune evasion strategies possessed by the virus to hijack the host immune response. The course of SARS-CoV infection may be developed into three subsequent stages. This classification is mainly based on the clinical signs and the viral loads in the collected samples from tested patients.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> During the first stage, the infected individual does not show any visible clinical signs and may have little or no viral load in their secretions. In the second stage, the patient starts to show apparent clinical manifestations with moderate viral loads detected in their secretions. In the final third stage, the affected individuals suffered from severe conditions, including the involvement of the lungs and many other organs (kidneys and intestine).<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> The outcomes of the infection are mainly fine-tuned by the immune status of the infected patients. The host immune response for the SARS-CoV-2 is developed in two phases.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> The first phase is triggered during the acute stage of the infection to enhancing the immune response in overcoming the viral infection. While the second phase started with the progression of the inflammatory reactions and damage of the target organs which may lead to the death of the infected patient.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup></p></sec><sec disp-level="1" id="s0002"><title>The biology of the SARS-CoV-2 is contributing to the control and mitigation of the virus infection and pathogenesis</title><p>
SARS-CoV-2-S protein is one of the leading viral proteins that play essential roles in the virus cycle, identification of the viral tropism, especially during the virus attachment, and the procedure of viral entry into the cell. It is one of the main targets for the vaccine, therapy, and diagnostic assays for most coronaviruses, including SARS-CoV-2. The viral cycle starts with the attachment of the spike glycoprotein with the viral receptors, the angiotensinogen converting enzyme-2 (ACE-2). Some other cellular factors favor virus entry, such as basigin (BSG). This is a newly discovered mechanism for the SARS-CoV-2 entry (CD147-SP).<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> The S protein is inert outside the host, which undergoes activation through the furin enzyme cleavage into the S1 and S2 subunits.<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> This step is crucial for the success of SARS-CoV-2 infection on the cellular level. Blocking the cleavage of the spike glycoprotein will inhibit the virus infection, thus representing an attractive potential target for drug design. The furin enzymes are highly expressed in the respiratory tract; thus, once the virus exits from one cell, it will be ready to enter another cell and potentiate the virus replication.<sup><xref rid="cit0008" ref-type="bibr">8</xref></sup> Preventing the SARS-CoV-2 virus attachment to the host cells can be done by several strategies. Using some fusion protein inhibitors is a promising trend in halting the SARS-CoV and MERS-CoV infection both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> in mouse models.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> Another important host factor is the transmembrane protease, serine 2 (TMPRSS2), which potentiates the viral infection by exposing the active sites of the spike glycoprotein to interact with the host cell and mediates the virus entry.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> Using the TMPRSS2 inhibitors recently proved to prevent the SARS-CoV-2 entry into the target cells. This is a new promising trend in the treatment of SARS-CoV-2.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> Another essential protein is the main protease -chymotrypsin-like cysteine protease (3CL<sup>pro</sup>). It plays an essential role during coronavirus replication. The sequence of this protein is most likely highly conserved among most coronaviruses. Using some 3&#160;CL pro inhibitors such as ledipasvir showed promising results in the inhibition of the SARS-CoV-2 replication.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> This is one of the promising therapeutic approaches for COVID-19 with minimal side effects.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> The N protein binds to the viral nucleic acids to form the nucleocapsid from which it acquires its name. This protein plays some essential roles during virus replication.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> This protein is highly phosphorylated, thus potentiates the binding with the viral RNA compared to other RNA molecules.<sup><xref rid="cit0014" ref-type="bibr">14</xref></sup> The immune response plays an essential role in fine-tuning the outcomes of any infection with different pathogens. There are two arms of the immune response; the innate and the adaptive responses. In the following sections, we will elaborate on some recent advances on the immune response against SARS-CoV-2, including the humoral as well as the cell-mediated immunity.</p></sec><sec disp-level="1" id="s0003"><title>The adaptive immune response in the context of SARS-CoV2 infection</title><p>
Typically, the adaptive immune response plays an important role in controlling and clearing several viral infections.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup> There are two types of reactions involved in adaptive immunity, including the cellular immune response, which is mediated by the T cells, and the humoral immune response, which is an antibody-mediated response.</p><sec disp-level="2" id="s0003-s2001"><title>The T cells mediated immune response</title><p>During the coronavirus infection, the antigen-presenting cells (APC), such as dendritic cells (DCS), can pick up the viral peptides and presented them in the context of the major histocompatibility (MHC) class-2. Subsequently, the CD4&#160;+&#160;T cells (T helper) can recognize these peptides and then subsequently being activated. Therefore, they produce several types of cytokines and chemokines. The cytokines produced by the CD4-T cells including several subsets (Th1, Th2, Th17, and T regulatory cells (T-regs)). The Th1 cells produce IFN-&#947;, whereas the Th2 cells produce some cytokines such as IL-4, IL-5, and IL-13 (<xref rid="f0001" ref-type="fig">Figure 1</xref>). The T-reg cells usually produce some suppressive cytokines such as IL-10 and TGF-&#946;. They have an essential role in the regulation and maintaining the immune response and therefore preventing autoimmunity.<sup><xref rid="cit0016" ref-type="bibr">16&#8211;18</xref></sup> Th17 producing some cytokines, including IL-17, IL-21, and IL-22.<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup> Furthermore, the CD4&#160;+&#160;T cells are activating the CD8&#160;+&#160;T cells by providing a co-stimulatory signal.<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> This stimulation is achieved through the interaction between the CD40L and the CD40 on the DCS. This interaction induces an up-regulation of some ligands, including CD80 and CD86. Both are expressed by the DCs, which came in contact with the CD28 expressed by the naive CD8 T cells.<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> CD4&#160;+&#160;T cells stimulate the B cells to produce some specific antibodies.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> Furthermore, the CD8 T cells can destroy the virus-infected cells.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> It has been shown that in the case of SARS-CoV patients, the CD8 T cells play an important role in the destruction and clearance of the infected cells within the pulmonary interstitium tissues.<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup> Moreover, the MERS-CoV infection of mice deficient in both T and B cells showed that the virus was not cleared from the lungs in the absence of T cells compared to control animals. This suggested the importance of T cells in the clearance of coronavirus infections.<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup> SARS-CoV infection in some CD8 deficient mice did not affect the viral load. Whereas depletion of the CD4 T cells resulted in the delay in the viral clearance and was associated with a marked reduction in the cytokines production. It also reduced the production of the viral-specific neutralizing antibodies as wells as a marked reduction in the recruitment of lymphocytes into the lung tissues. This suggests the pivotal role of the CD4 rather than the CD8 during the early stages of the SARS-CoV infection.<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> One study conducted on 128-SARS-CoV survived individuals revealed the convalescent samples showed that the CD8&#160;+&#160;T cell was higher and more prominent than the CD4&#160;+&#160;T cell. The severely affected individuals developed higher levels of central memory T cells and were associated with a higher functional activity of both CD4 and CD8-T cells. This pattern was in comparison to the mildly and moderately affected group of patients who showed a strong T cells response in about 70% of cases. This is in addition to, high level of specific antibodies against most of the structural proteins of the virus, including (S, E, M, and N). However, the Th2 cytokines, including IL-4, IL-5, and IL-10, were highly expressed in more severe and fatal cases.<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup> Surprisingly, the role of Th17 during the SARS-CoV infection was not fully defined yet. However, the IL-17 levels were elevated in the serum of some COVID-19 patients.<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> The SARS-CoV-2 infection triggered an exaggerated immune response in the infected patients called cytokines storm (<xref rid="f0001" ref-type="fig">Figure 1</xref>) or macrophage activation syndrome (MAS).<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> It is may also be known as secondary haemophagocytic lymphohistiocytosis (sHLH).<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> This condition may lead to acute respiratory distress syndrome (ARDS), which contributed substantially to the outcomes of the virus infection in diseased individuals.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup><fig position="float" id="f0001" fig-type="figure" orientation="portrait"><label>Figure 1.</label><caption><p>The proposed diagram of the innate and adaptive immune response to SARS-CoV2 infection</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="color" specific-use="web-only" position="float" orientation="portrait" xlink:href="KHVI_A_1935172_F0001_OC.jpg"/><graphic xmlns:xlink="http://www.w3.org/1999/xlink" content-type="black-white" specific-use="print-only" position="float" orientation="portrait" xlink:href="KHVI_A_1935172_F0001_PB.jpg"/></alternatives></fig></p></sec></sec><sec disp-level="1" id="s0004"><title>Cytokine storm and the severity of COVID-19</title><p>
Moreover, there is a direct relationship between the cytokines storm and the severity of COVID-19 infections and fatal outcomes.<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup> During severe COVID-19 cases, both IL-6 and IL-1 levels are dramatically increased compared to the mild or moderate groups of patients. This pattern suggests the important roles of this cytokine as a marker for the severity of clinical cases. It may also have used in assessment and the prognosis of the SARS-CoV-2 infection.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0032" ref-type="bibr">32</xref></sup> Therefore, targeting IL-6 or its receptor (IL-6&#160;R) with specific monoclonal antibodies, such as (Tocilizumab, Siltuximab) may result in reducing the severity of the airway inflammation and consequently reduce the severity of the disease.<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup> Further studies are required in order to enrich our understanding of the interaction between SARS-CoV2 and the host cells. This may lead us to achieve better knowledge in regard to the cytokines response mediate by the host-infected cells and how may the virus escape from the immune recognition. Moreover, one study was conducted on the peripheral blood mononuclear cells (PBMCs) isolated from SARS-CoV recovered individuals. This study showed that SARS-specific memory T cells against most viral structural proteins, including membrane (M) and Nucleocapsid (N) protein, were detectable up to 11&#160;years after SARS-CoV infection. These findings suggestion the SARS-CoV recovered patients may be protected against the subsequent re-infection with homologs viral strain.<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup> This may support the theory of vaccination against SARS-CoV as an important aid in the prophylaxis of such viruses and their related viruses.</p><p>Both SARS-Co-V and SARS-CoV-2 can directly infect both the macrophages and the T cells, which contributed substantially to the pathogenicity of these viruses.<sup><xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0035" ref-type="bibr">35</xref></sup> Recent studies on some SARS-CoV-2 patients showed that the number of both CD4&#160;+&#160;T and CD8&#160;+&#160;T in the peripheral blood sharply decreased, although their status remained active, and the CD8&#160;+&#160;T cells are becoming more cytotoxic.<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup> Thus, there is an urgent need to fine-tune and control the CD8 T cell responses to minimize and avoid as much as possible any lung tissue damage and injury. Additionally, it has been revealed that the number of the T cells was decreased in the case of the severely affected SARS-CoV-2 patients, including the TH and the T reg cells. Whereas, the percentage of na&#239;ve Th cells was increased, and the memory Th was decreased in severe cases of SARS-CoV-2 infection.<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup> T cells were reported to express the SARS-CoV-2 receptors, such as ACE-2 and CD147.<sup><xref rid="cit0033" ref-type="bibr">33</xref>,<xref rid="cit0037" ref-type="bibr">37</xref></sup> This might be one of the main reasons behind the dramatic decrease in the total numbers of T-cells count in the case of the severely affected SARS-CoV-2 patients.</p></sec><sec disp-level="1" id="s0005"><title>Mapping and identification of neutralizing epitopes in SARS-CoV-2 and its applications in the vaccines and diagnostic assays development</title><p>During MERS-CoV infection, the CD8-T-cell production was largely increased during the early stage of the infection and was usually associated with severe cases of infection; however, during the recovery phase, the Th1 cell was notably observed.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup> Interestingly, both SARS-CoV and MESR-CoV can produce specific CD4 memory cells against some conserved epitopes shared by both viruses. Therefore, mice were protected against the challenge of the wild types of these viruses. These shared epitopes induce neutralizing antibodies that can cross-react with MESR-CoV and SARS-CoV, suggesting the potential role of these conserved peptides as vaccines against most of the coronaviruses.<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup> Since most of these epitopes recognized the antigenic counterparts within most structural proteins of both SARS-CoV and MERS-CoV, a similar approach may be adopted in the case of the SARS-CoV-2. Mapping these neutralizing epitopes within the three viruses (SARS-CoV, MERS-CoV, and SARS-CoV-2) may pave the way for several potential vaccines against SARS-CoV-2. In a similar trend, it may highlight the promising trends of using serum and plasma of the recovered patients as potential therapeutic interventions against SARS-CoV-2 infection. A new study showed a promising trend of using some single antibody domains isolated from Illama immunized with the coronaviruses spike protein in vitro.<sup><xref rid="cit0040" ref-type="bibr">40</xref></sup> These potent antibodies protected the cells from infection with the SARS-CoV-2 infection by preventing the virus entry into the cells.<sup><xref rid="cit0040" ref-type="bibr">40</xref></sup></p><p>In conclusion, although the three coronavirus candidates (SARS-CoV, MERS-CoV, and SARS-CoV-2) are belonging to the same family, there is a differential display of their downstream immunological profiles, which contribute to the severity and outcomes of the viral infection for each virus.</p><sec disp-level="2" id="s0005-s2001"><title>The B cells mediated immune response</title><p>The B cell immune response plays key role in the protection against the subsequent SARS-CoV-2 infection through the production of viral-specific antibodies.<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup> These antibodies were able to neutralize the viral infectivity, therefore, prevent the virus attack to the host cells.</p><p>Although few serological studies were conducted on the SAR-CoV-2 at this time, some studies were conducted to monitor the antibody levels in some patients. These studies showed that the specific IgM antibody reached its peak 9-day post-infection. While the IgG level increased in about two weeks and lasted up to 20&#160;days after infection. The serum containing antibodies collected from confirmed COVID-19 patients appeared to cross-reactive with SARS-CoV and not with other coronaviruses members. Moreover, <italic toggle="yes">in vitro</italic> studies on sera from those patients were also able to neutralize the SARS-CoV infectivity in cell culture. This suggests cross-reactivity between both SARS-CoV and SARS-CoV-2.<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup> Another study was conducted on one patient infected with SARS-CoV-2 to monitor the curve of neutralizing antibodies of IgM and IgG classes against (S) and (N) proteins of SARS-CoV. This study revealed that the level of these antibodies in sera of this patient was low on day four after infection, which increased at day 9, then dropped to non-detectable levels on day 20 in the case of IgG.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> In the same context, another independent study also reported that at day 0, the titters of the IgM and the IgG were undetectable or even very low then increased by the fifth day of infection, whereas the IgG levels were increased in all the patients.<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup> However, in the case of SARS-CoV infection, the starting of the antibody production against the virus is varied among different classes of antibodies. In the case of IgM, it ranged from 3 to 42&#160;days post-infection. Whereas in the case of the IgG, it ranges from 5 to 47&#160;days.<sup><xref rid="cit0044" ref-type="bibr">44</xref></sup> In conclusion, there is a differential display in the kinetic of various classes of antibodies between SARS-CoV and SARS-CoV-2. These data may explain at least in part the differential clinical outcomes of infection of those two viruses.</p><sec disp-level="3" id="s0005-s2001-s3001"><title>Immunity to the reinfection in the context of SARS-CoV-2</title><p>It is not clear whether the primary infection with SARS-CoV-2 may provide long-term protection against the re-infection or not yet. The re-infection of monkeys on day 28 after the initial SARS-CoV-2 infection revealed the same result in the protection of these animals against the second round of infection with the virus (<xref rid="f0001" ref-type="fig">Figure 1</xref>).<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> This was suggesting the potential roles of the immune response in the protection against re-infection with the SARS-CoV; however, these findings require further clarification in case of human infection. Thus, longitudinal cohort studies are urgently required to clarify whether the primary SARS-CoV-2 infection may provide enough long-lasting protection upon any subsequent infection.</p></sec><sec disp-level="3" id="s0005-s2001-s3002"><title>Applications of convalescent sera and monoclonal antibodies in the treatment of COVID-19</title><p>The human convalescent serum is considered a potential opportunity for the treatment of COVID-19 patients. This may be achieved through the collection of sera from the recovered COVID-19 patients where the neutralizing antibodies are present against SARS-CoV-2 and administered to some new patients to help them overcome the active infection, especially in the more severe cases.<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> Additionally, it has been reported that the administration of SARS-CoV-2 convalescent sera from recovered patients helped in the alleviation and subsidy of severing active COVID-19 infections.<sup><xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0047" ref-type="bibr">47</xref></sup> Although human convalescent serum is a promising approach in the treatment of SARS-CoV-2 infection, there are some limitations related to this method. These concerns include the possibility of transferring other pathogens to the recipient patients, the potential activation of some antibody-dependent enhancement (ADE). This process may suppress the anti-innate immune responses as it was reported in some <italic toggle="yes">in vitro</italic> studies done earlier on SARS-CoV.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> Other factors related to the adjustment and fine-tuning of the administered volumes, titers, and time of transfusion of plasma from the donor to the recipient patients.<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> The convalescent serum approach, using passive immunization by specific monoclonal antibodies is more specific, safe, and has a low risk of transfer other potential pathogens. Furthermore, using cocktail monoclonal antibodies (Mab) of the SARS-CoV-2 that are able to recognize several epitopes may increase the efficiency of these neutralizing (Mab) antibodies.</p></sec><sec disp-level="3" id="s0005-s2001-s3003"><title>Kinetics of SARS-CoV-2 memory cell responses</title><p>Regarding B cell response, a recent study reported that all serum patients relative to uninfected controls had a significant proportion of specific B memory cells against RBD and NCP. These B cell populations have both un-switched class (CD27+&#160;IgM IgD) and switched class cells (CD27+&#160;IgD) which contained IgG expressing B memory cells.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> Effective and predominant B memory cells response are induced by SARS-CoV-2 infections, which contained IgM and IgG-specific B memory cells against RBD and NCP. Furthermore, the B memory cells against RBD are nearly CD27+&#160;and correlated positively with T follicular helper cells (Tfh).<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> Serum antibodies have decreased gradually following SARS-CoV-2 clearance. However, specific memory B cells are detected over time in a stable proportion.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup></p><p>It has shown that memory response against SARS-CoV-2 lasts for 8&#160;months and spike-specific IgG antibodies were stable and circulated for up to 6&#160;months post-SARS-CoV-2 infection. Also, B memory cell counts were abundant at 6&#160;months rather than the first month especially post-viral symptoms appearance. The proportion of RBD-specific IgG was 88% between 6 and 8&#160;months.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> On the other hand, IgA levels were assessed in most COVID-19 patients, started to increase on day 27, and disappeared by 3 months. B cells appeared on day 16 early after the onset of viral symptoms and increased and become stable in the following 4&#8211;5&#160;months.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> 10&#8211;30% of memory B cells in recovery patients were specifically for RBD antigens. Antibody titers (IgG) decreased after 6&#8211;8&#160;months post symptoms onset among individuals but is highly heterogeneous among them.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> Another study has demonstrated that CD19&#160;+&#160;B cell numbers were higher in severe COVID-19 than mild cases. Memory B cells were low in severe and critical cases, but the plasma cells were high, due to the disease severity. Overall the total number of B cells in COVID-19 patients (different categories (mild, severe, and critical) was lower than healthy donors, suggesting that preexisting memory B cells specific for other coronavirus were activated and differentiated to atypical memory (CD27<sup>&#8722;</sup>) and/or plasma cells.<sup><xref rid="cit0052" ref-type="bibr">52</xref></sup> Taking together, memory B cells might be represented the long-lived humoral response than serum antibodies and could be used as robust and substitute markers of humoral immunity in immunization studies.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> In contrary to other studies that reported a decrease in B cell numbers during COVID-19,<sup><xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0054" ref-type="bibr">54</xref></sup> there was no reduction of B cells in all patients and serum that collected within 14&#160;days of symptoms appearance.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup></p><p>Based on the presented research about the SARS-CoV-2 memory cells, it is concluded that both previous infections and vaccination against the virus may provide a considerable level of immunity against the virus however, large-scale studies are required to map the kinetics of the memory cells among the infected and vaccinated individuals.</p></sec></sec></sec><sec disp-level="1" id="s0006"><title>Some SARS-CoV-2 immune evasion strategies</title><p>Both SARS-CoV and MERS-CoV evade the immune response in many ways.<sup><xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0055" ref-type="bibr">55</xref></sup> Here, we are presenting some immune evasion strategies posed by those closely related viruses to the SARS-CoV-2. These evasion strategies help the SARS-CoV-2 to hijack the host immune response and contribute to the progress and promotion of its replication cycle. These strategies may also contribute to the lethality and virulence of SARS-CoV-2 infected patients. The SARS-CoV-2 induces severe pathology in many vital organs of the affected patients, especially lungs, kidneys, and, heart, brain, intestines.<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup> There might be some virulent virus factors produced by the virus to induce this multi-organ failure.</p><p>Meanwhile, the SARS-CoV-2 utilizes some unique immune evasion strategies that may contribute to the virulence and lethality of this virus. Recent studies revealed SARS-CoV-2 infection-induced differential display of some crucial blood and immune markers. The infected patients had an increase in the neutrophils, IL-6, and the serum reactive protein (CRP). However, those patients showed a 35% reduction in the total numbers of circulating lymphocytes.<sup><xref rid="cit0056" ref-type="bibr">56</xref></sup> These parameters act as biomarkers for the SARS-CoV-2 infection. They may be used for monitoring the progress of the treatment of infected patients. Both SARS-CoV and MERS-CoV possess some immune evasion strategies through the production of the double-membrane vesicles, which contain the virus replication complex. Those viruses escape the host immune system detection through the replication inside these vesicles.<sup><xref rid="cit0057" ref-type="bibr">57</xref></sup> Another interesting phenomenon is the inhibition of the IFN-I pathway by the MERS-CoV- ORF-4a.<sup><xref rid="cit0058" ref-type="bibr">58</xref></sup></p><p>Furthermore, both MERS-CoV and influenza virus (H5N1) decrease the expression of the antigen presentation.<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> The SARS-CoV-2 infection triggers similar pathways to ensure the success of its replication cycle; however, further studies are required to confirm these findings. In the same context, the MERS-CoV- 4b interferes with the NF-&#954;B pathway resulting in the counteraction of the host&#8217;s innate immune response against the virus infection.<sup><xref rid="cit0060" ref-type="bibr">60</xref></sup> A new study showed the coexistence of the viral RNA in saliva and specific antibodies in sera of patients recovered from SARS-CoV-2 for up to 40&#160;days after the recovery of some infected patients. These findings suggest some unique immune evasion strategies adapted by the virus to hijack the host immune response, thus remain active even after the recovery of the patient.<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> More studies are required to confirm these findings and to reveal the mechanism behind these phenomena.</p></sec><sec disp-level="1" id="s0007"><title>Roles of various SARS-CoV-2 proteins in the immune evasion and hijacking the host immune response</title><p>Recent studies showing that various SARS-CoV-2 proteins including some structural and the nonstructural proteins may contribute to the virus immune evasion strategies (<xref rid="t0001" ref-type="table">Table 1</xref>) which enhance the virus replication and promotes its pathogenesis and spread.<sup><xref rid="cit0062" ref-type="bibr">62</xref>,<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0069" ref-type="bibr">69</xref>,<xref rid="cit0070" ref-type="bibr">70</xref></sup> SARS-CoV-2-ORF8 plays important functions during virus replication and in viral immune evasion.<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> This may affect the downstream pathogenesis of the virus. It mediates the degradation of the MHC-class-I and contributes to the marked inhibition of the IFNs production. These effects fine-tune the outcomes of the virus infection.<sup><xref rid="cit0067" ref-type="bibr">67</xref></sup> SARS-CoV-ORF-3 plays an important role during the virus infection and pathogenesis through its actions on the JAK-STAT, chemokine, and cytokine- pathways.<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> Mutations within the SARS-CoV-ORF-3 are associated with high case fatality rates among the affected individuals.<sup><xref rid="cit0066" ref-type="bibr">66</xref></sup> Both SARS-CoV-2-NSP-2 and NSP-6 act synergistically to inhibit the INFs production in a much more efficient way than the SARS-CoV and MERS-CoV.<sup><xref rid="cit0063" ref-type="bibr">63</xref></sup> There is an active interaction between the NSP16 and the NSP-10 in the context of SARS-CoV-2 infection. This interaction creates some unique binding pocket sites for the virus activation and contributes to the viral immune evasions.<sup><xref rid="cit0065" ref-type="bibr">65</xref></sup> SARS-CoV-NSP-1 binds to various host cell ribosomes subunits resulting in the shutdown of some host cell genes both <italic toggle="yes">in-vitro</italic> and <italic toggle="yes">in vivo</italic>.<sup><xref rid="cit0062" ref-type="bibr">62</xref></sup> SARS-CoV-2-ORF-9&#160;C is a transmembrane protein that recently showed to play important immune evasion roles during the virus infection.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> It is the first coronavirus-ORF-9&#160;C to induces its downstream effects through tackling the interferon signaling pathways.<sup><xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0069" ref-type="bibr">69</xref></sup> The SARS-CoVNSp-15<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1.</label><caption><p>Summary of some immune evasion effects of various SARS-CoV-2 proteins</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">N</th><th align="center" colspan="1" rowspan="1">Protein</th><th align="center" colspan="1" rowspan="1">Type</th><th align="center" colspan="1" rowspan="1">Immune evasion effects</th><th align="center" colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">NSP-1</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Binds to ribosomal subunits resulting in the shutdown of some host cell protein synthesis</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0062" ref-type="bibr">62</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">NSP-2</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Inhibits IFNs production</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0063" ref-type="bibr">63</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">NSP-3 (PLp)</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Post-translation modification of host cell proteins<break/>Affect the NFKb and IFNs pathways</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0064" ref-type="bibr">64</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">NSP-6</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Inhibits IFNs production</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0063" ref-type="bibr">63</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">NSP-10</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Contribute to the formation of the unique binding pocket sites with NSP-16</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0065" ref-type="bibr">65</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">ORF3</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Affect the JAK-STAT, chemokine, and cytokine- pathways</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0066" ref-type="bibr">66</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">ORF8</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">Degradation of the MHC-I<break/>Inhibition of the IFNs pathways</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0067" ref-type="bibr">67</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">NSP-15</td><td align="left" colspan="1" rowspan="1">NSP</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">NSP-16</td><td align="left" colspan="1" rowspan="1">NS</td><td align="left" colspan="1" rowspan="1">Contribute to the formation of the unique binding pocket site with NSP-10</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0065" ref-type="bibr">65</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">9</td><td align="left" colspan="1" rowspan="1">S</td><td align="left" colspan="1" rowspan="1">SP</td><td align="left" colspan="1" rowspan="1">Conformtionalcahnges and glycosylation enable the spike protein to induce evasion of the host immune response</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0068" ref-type="bibr">68</xref></sup></td></tr><tr><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1">M</td><td align="left" colspan="1" rowspan="1">SP</td><td align="left" colspan="1" rowspan="1">Possesses sugar transporter-like to enhance virus replication and immune evasion</td><td align="left" colspan="1" rowspan="1"><sup><xref rid="cit0069" ref-type="bibr">69</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>NSP&#160;=&#160;none structural protein.</p></fn><fn id="tfn0002"><p>SP&#160;=&#160;structural protein.</p></fn></table-wrap-foot></table-wrap>
</p><p>Play important roles in the RNA processing and host immune evasion. Repurposing of some drugs using the in silico analysis showed that targeting the NSP-15 of the virus may have promising trends in the control of SAR-CoV-2 infection.<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup> SARS-CoV2-PLpro (papin like protease) plays important role in the process of post-translation modification of viral and host cell proteins. It also contributes to the regulation of the IFN and NFKB pathways which enhancing the progression of virus replication and immune evasion.<sup><xref rid="cit0064" ref-type="bibr">64</xref></sup> Thus, targeting this protein may represent one of the promising trends in controlling virus infection within the host.<sup><xref rid="cit0064" ref-type="bibr">64</xref></sup> The SARS-CoV-2-S protein undergoes a process of posttranslational glycosylation which plays important role in the virus infection, pathogenesis, and host immune system evasion.<sup><xref rid="cit0068" ref-type="bibr">68</xref></sup> Recent studies showing the SARS-CoV-2-M protein possesses sugar transporter-like which have a substantial impact on virus replication and host immune evasion.<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup></p></sec><sec disp-level="1" id="s0008"><title>SARS-CoV-2 vaccine candidates</title><p>Since the emergence of SARS-CoV-2, scientists all over the world and vaccine development companies are in a battle working day and night to achieve this milestone. The rationale behind the vaccination strategy is to immunize the at-risk people, especially the immunocompromised, elderly, and health care workers in the front line of combating this virus. Although there are six other human coronaviruses identified from long time, there are no available licensed vaccines against any of them despite some new trials for vaccines against MERS-CoV recently developed and are in the clinical trials.<sup><xref rid="cit0073" ref-type="bibr">73</xref>,<xref rid="cit0074" ref-type="bibr">74</xref></sup> Typically, vaccine development is a lengthy procedure and requires many steps, including laboratory testing preclinical and clinical trials. At this time, to speed up the procedures of making successful SARS-CoV-2 vaccines. Perhaps some of the preclinical studies were performed in parallel with clinical trials; however, many obstacles were hampering these procedures, such as the regulatory authorities must assess the vaccine manufacturing process and preclinical data to ensure the safety of volunteer persons.<sup><xref rid="cit0075" ref-type="bibr">75</xref></sup></p></sec><sec disp-level="1" id="s0009"><title>History of the development, testing, evaluation, and approval of some SARS-CoV-2 vaccines</title><p>There are many strategies for vaccine preparation and development for many viruses. Some of these strategies may be applicable for coronaviruses, including (i) the live-inactivated, (ii) the subunit vaccines, and (iii) the nucleic acid-based vaccines. On Jan 23rd, 2020, the Coalition for Epidemic Preparedness Innovations (CEPI) has declared the funding to develop some vaccines against SARS-CoV-2 using three different approaches, including DNA, mRNA, and molecular clamp.<sup><xref rid="cit0076" ref-type="bibr">76</xref></sup> As of April 2020, more than 20 potential SARS-CoV-2 vaccine candidates have been published worldwide (<xref rid="t0002" ref-type="table">Table 2</xref>). As of April 2020, several COVID-19 vaccine candidates were approved and currently in the clinical trials at different phases. Currently, there are at least 10 SARS-CoV-2 approved vaccines and deployed in many parts across the world. Finally, we now have several SARS-CoV-2 vaccines approved and deployed in one of the largest global vaccination campaigns ever. As of Dec 23rd, 2020, there are 2013 vaccine candidates for SARS-CoV-2 under development. Almost 44 out of them are in varying stages of the clinical trials.<sup><xref rid="cit0086" ref-type="bibr">86</xref></sup> A strong network of international coordination and cooperation between academia, vaccine developers, public health institutes, and government bodies urgently needed to make sure that an effective vaccine may be developed as soon as possible to stop the spread of SARS-CoV-2 across the globe thus the current SARS-CoV-2 pandemic can be contained.<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2.</label><caption><p>Top ranked SARS-CoV-2 vaccines</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="left" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/><col width="1*" align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">N</th><th align="center" colspan="1" rowspan="1">Platform</th><th align="center" colspan="1" rowspan="1">Current status</th><th align="center" colspan="1" rowspan="1">No of doses</th><th align="center" colspan="1" rowspan="1">Prime post intervals/days</th><th align="center" colspan="1" rowspan="1">Current status</th><th align="center" colspan="1" rowspan="1">Country of origin</th><th align="center" colspan="1" rowspan="1">Storage temperature</th><th align="center" colspan="1" rowspan="1">Efficacy*</th><th align="center" colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">I</td><td colspan="7" align="left" rowspan="1"><bold>mRNA vaccine</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">BioNTech/Fosun Pharma/Pfizer</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">USA, Germany, China</td><td align="center" colspan="1" rowspan="1">(&#8722;80) &#176;C</td><td align="center" colspan="1" rowspan="1">95%</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0077" ref-type="bibr">77</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Moderna/National Institute of Allergy and Infectious Diseases</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">USA</td><td align="center" colspan="1" rowspan="1">(&#8722;15/-20) &#176;C</td><td align="center" colspan="1" rowspan="1">94.1%</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0078" ref-type="bibr">78</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">II</td><td colspan="7" align="left" rowspan="1"><bold>Recombinant viral vector vaccines</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Astra-Zeneca</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">28/84</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">UK</td><td align="center" colspan="1" rowspan="1">2&#8211;8&#176;C</td><td align="center" colspan="1" rowspan="1">50.4%</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0079" ref-type="bibr">79</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">CanSino Biological Inc</td><td align="center" colspan="1" rowspan="1">1</td><td align="center" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1">China</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">96.1%</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0080" ref-type="bibr">80</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">Johnson &amp; Johnson</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">56</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">USA</td><td align="center" colspan="1" rowspan="1">2&#8211;8&#176;C</td><td align="center" colspan="1" rowspan="1">&#8722;50.4% in symptomatic<break/>-78% mild cases<break/>-100% severe cases</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0081" ref-type="bibr">81</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">Sputnik-V</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">Russia</td><td align="center" colspan="1" rowspan="1">2&#8211;8&#176;C</td><td align="center" colspan="1" rowspan="1">92%</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0082" ref-type="bibr">82</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">III</td><td colspan="7" align="left" rowspan="1"><bold>Inactivated vaccines</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Sinovac</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">China</td><td align="center" colspan="1" rowspan="1">4&#176;C</td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0083" ref-type="bibr">83</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">Sinopharm</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">21</td><td align="left" colspan="1" rowspan="1">Deployed</td><td align="left" colspan="1" rowspan="1">China</td><td align="center" colspan="1" rowspan="1">&#176;C</td><td align="center" colspan="1" rowspan="1">86</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0084" ref-type="bibr">84</xref></td></tr><tr><td align="left" colspan="1" rowspan="1">IV</td><td colspan="7" align="left" rowspan="1"><bold>Subunit vaccines</bold></td><td align="center" colspan="1" rowspan="1">&#160;</td><td align="center" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">Novavax</td><td align="center" colspan="1" rowspan="1">2</td><td align="center" colspan="1" rowspan="1">28</td><td align="left" colspan="1" rowspan="1">Phase III</td><td align="left" colspan="1" rowspan="1">USA, UK, South Africa</td><td align="center" colspan="1" rowspan="1">(&#8722;70) &#176;C</td><td align="center" colspan="1" rowspan="1">&#8722;96.4% /original strain<break/>-86.3 /UK variant<break/>-48.6%/SA variant</td><td align="center" colspan="1" rowspan="1"><xref rid="cit0085" ref-type="bibr">85</xref></td></tr></tbody></table><table-wrap-foot><fn id="tfn0003"><p>*Efficacy mainly based on the prevention of severe COVID-19 syndromes but not the SARS-CoV-2 infection.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec disp-level="1" id="s0010"><title>Some potential nucleic acid-based SARS-CoV-2 vaccines</title><p>The nucleic acid-based vaccines are the most advanced platforms for the response to emerging viral pathogens. For example, during the Zika virus outbreak, nucleic acid-based vaccines were the first vaccine candidates that entered clinical trials in less than 1 year after the emergence of the epidemic.<sup><xref rid="cit0087" ref-type="bibr">87</xref></sup> Some SARS-CoV-2 nucleic acid-based vaccine platforms are developed. The Moderna Therapeutics, CureVac, and Shanghai East Hospital (Tongji University) Stermirna Therapeutics are exploring the mRNA vaccine platforms.<sup><xref rid="cit0056" ref-type="bibr">56</xref></sup></p></sec><sec disp-level="1" id="s0011"><title>Some SARS-CoV-2 mRNA deployed vaccines</title><p>The mRNA-1273 vaccine was developed by Moderna Therapeutics and the US National Institute of Allergy and Infectious Diseases (NIH).<sup><xref rid="cit0088" ref-type="bibr">88</xref></sup> This COVID-19 vaccine RNA-1273 is an mRNA vaccine expressing COVID-19 spike protein. This vaccine phase I clinical trial was initiated at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. Simply, the vaccine was constructed to encode the SARS-CoV-2 gene and encapsulated with lipid nanoparticles for delivery into the host cells.<sup><xref rid="cit0089" ref-type="bibr">89</xref></sup> This vaccine showed a high degree of prevention of the severe COVID-19 cases up to 94.1% (<xref rid="t0002" ref-type="table">Table 2</xref>). This was a great leap for lowering the number of hospitalizations among infected patient especially severe cases require admission to the intensive care units.<sup><xref rid="cit0089" ref-type="bibr">89</xref></sup> Another promising vaccine is the BNT162b2 mRNA. This vaccine developed through the nucleoside-modified RNA encoding the full-length SARS-CoV-S gene coupled with some lipid nanoparticle.<sup><xref rid="cit0077" ref-type="bibr">77</xref></sup> This vaccine is showing 95% protection against the development of severe COVID-19 cases.<sup><xref rid="cit0077" ref-type="bibr">77</xref></sup></p><p>Both vaccines are currently deployed in many parts int eh world. They administered on a prime-boost regimen 21&#160;days apart.<sup><xref rid="cit0090" ref-type="bibr">90</xref></sup></p></sec><sec disp-level="1" id="s0012"><title>Some recombinant SARS-CoV-2 vaccines</title><p>Another approved vaccine established by the Cansino Biologics Inc, the Academy of Military Medical Sciences of China, named Ad5-nCoV. This vaccine is mainly based on a vector containing a defective adenovirus-5 that expresses the spike protein of the SARS-CoV-2. Finally, the University of Oxford in combination with AstraZeneca company, developed and deployed the ChAdOx1-nCoV-19 vaccine.<sup><xref rid="cit0091" ref-type="bibr">91</xref></sup> This approach has been used recently to develop a vaccine against MERS-CoV.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> This ChAdOx1-nCoV-19 vaccine showed promising results in protecting some rhesus macaques from experimental infections with the SARS-CoV-2.<sup><xref rid="cit0088" ref-type="bibr">88</xref></sup> The clinical human trials for these vaccines showed a high rate of protection (88%) against the severe COVID-19 cases when administered in a prime-boost regimen (<xref rid="t0002" ref-type="table">Table 2</xref>).<sup><xref rid="cit0091" ref-type="bibr">91</xref></sup> These studies suggested that the maximum performance of this vaccine can be achieved in a prime-boost regimen 28&#160;days apart.<sup><xref rid="cit0092" ref-type="bibr">92</xref></sup></p></sec><sec disp-level="1" id="s0013"><title>Some potential live virus and recombinant SARS-CoV-2 vaccines</title><p>One potential common vaccine candidate for coronaviruses may be developed based on the similarities between the T-cell epitopes of SARS-CoV and MERS-CoV. It may also depend on the possibility of cross-reactivity between these viruses.<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup> A recent study identified some candidate vaccines design based on the high degree of genetic similarity between the SARS-CoV and the SARS-CoV-2.<sup><xref rid="cit0093" ref-type="bibr">93</xref></sup> By screening SARS-CoV-derived B and T cell epitopes, they identi&#64257;ed some promising candidates derived from the spike (S) and nucleocapsid (N) proteins that showed a high degree of similarity to SARS-CoV-2 proteins.<sup><xref rid="cit0093" ref-type="bibr">93</xref></sup> It is well documented that the spike (S) glycoprotein or S protein is the primary inducer of neutralizing antibodies and T-cell responses in several SARS-CoV vaccines. This includes the use of full-length S protein or S1 receptor-binding domain (RBD) and expression in virus-like particles (VLP), DNA, or viral vectors.<sup><xref rid="cit0094" ref-type="bibr">94</xref></sup> The Johnson &amp; Johnson Company has recently released its SARS-CoV-2 vaccine using the Janssen&#8217;s-AdVac&#174; adenoviral vector used previously to develop their Ebola virus vaccine. This vaccine has been approved by many countries. The University of Hong Kong has also launched a modified nasal spray influenza vaccine expressing a surface antigen from the SARS-CoV-2 protein. Besides, Codagenix has established a &#8220;codon de-optimization&#8221; vector method to abolish the virus virulence and to explore this SARS-CoV-2 vaccine strategy.<sup><xref rid="cit0095" ref-type="bibr">95</xref></sup> This type of vaccine has proven to be highly effective and provides long-lasting protection. One of the significant advantages of the whole virus vaccine is the activation of the T-cells responses, including CD4<sup>+</sup> and CD8<sup>+</sup> T, offering specific neutralizing antibodies, and memory B cell responses. Furthermore, it can trigger toll-like receptors (TLRs), such as TLR 3, TLR 7, TLR-8, and TLR 9. However, the attenuated pathogen may cause disease, as was reported with the oral polio vaccine.<sup><xref rid="cit0096" ref-type="bibr">96</xref></sup> A recent study used the recombinant parainfluenza virus-5 (PIV-5) backbone for the delivery of the MERS-CoV-S protein. This study showed excellent protection of the mice challenged with lethal MERS-CoV after a single intranasal administration of this recombinant vaccine.<sup><xref rid="cit0097" ref-type="bibr">97</xref></sup> This approach could be one of the new promising vaccination approaches for the SARS-CoV-2.</p></sec><sec disp-level="1" id="s0014"><title>SARS-CoV-2 inactivated vaccines</title><p>The inactivated vaccine is one of the classical vaccination strategies developed a long time ago and was applicable for many pathogens, including respiratory pathogens such as the influenza virus.<sup><xref rid="cit0098" ref-type="bibr">98</xref></sup> One of the main advantages of this approach is the preservation of the spike protein conformational epitopes in their original forms. This will result in the production of specific neutralizing antibodies against the original virus, as in the case of MERS-CoV.<sup><xref rid="cit0098" ref-type="bibr">98</xref></sup> Several inactivated SARS-CoV-2 vaccine candidates were tested for their efficacy and side effects.<sup><xref rid="cit0099" ref-type="bibr">99</xref></sup> Those two vaccines were developed by both the Beijing Institute of Biological Products Co., Ltd and the Wuhan Institute of Biological Products Co., Ltd. The clinical trials of those two vaccines revealed no safety concerns reported in the people who received those two vaccines.<sup><xref rid="cit0099" ref-type="bibr">99</xref></sup> The Sinovac Life Sciences, Beijing, China, developed an inactivated SARS-CoV-2 vaccine called CoronaVac.<sup><xref rid="cit0100" ref-type="bibr">100</xref></sup> Both phase I and II clinical trials for the CoronaVac revealed potential efficacy and safety in the vaccinated individuals.<sup><xref rid="cit0100" ref-type="bibr">100</xref></sup> Another recent study reported the encouraging trend of a new inactivated SARS-CoV-2 vaccine candidate prepared by the (PiCoVacc) company. They used the purified ten SARS-CoV-2 strains then inactivate them by beta-Propriolactone. This study showed this vaccine protects the non-human primates against the circulating strains of SARS-CoV-2.<sup><xref rid="cit0097" ref-type="bibr">97</xref></sup></p></sec><sec disp-level="1" id="s0015"><title>Some SARS-CoV-2 subunit vaccines</title><p>The subunit vaccines usually consist of purified antigens in the form of saccharides or conjugated proteins. They are generally prepared from viral synthetic peptides or recombinant proteins. The spike protein is the crucial player in viral pathogenesis, as well as the immune response. It is an ideal target for vaccine preparation using various strategies as well as diagnostic assays.<sup><xref rid="cit0055" ref-type="bibr">55</xref>,<xref rid="cit0101" ref-type="bibr">101</xref></sup> The DNA vaccine is much safer than other types of vaccines due to the absence of any microbial reversion and side effects. The key antigen in the subunit vaccine should be capable of inducing protective immune responses against a specific pathogen.<sup><xref rid="cit0097" ref-type="bibr">97</xref></sup> This vaccine candidate was used against SARS-CoV to stimulate a potent immune response against the spike proteins; as a result, neutralizing the binding site of viral protein and preventing its interaction with its specific receptor ACE2.<sup><xref rid="cit0102" ref-type="bibr">102</xref></sup> Some SARS-CoV-2 subunit vaccines are in the clinical stage, such as the vaccine developed by Queen&#8217;s land University using Rapid Response Technology, the &#8216;Molecular clamp&#8217; vaccine platform.<sup><xref rid="cit0103" ref-type="bibr">103</xref></sup> This technology can present the target vaccine straight forward to the immune system to induce a specific antibody response against the SARS-CoV-2.<sup><xref rid="cit0103" ref-type="bibr">103</xref></sup> Meanwhile, the</p><p>Clover Biopharmaceuticals is also working on developing a highly purified recombinant SARS-CoV-2-S protein subunit-trimer vaccine called (S-Trimer) through using their Trimer-Tag&#169; technology.<sup><xref rid="cit0104" ref-type="bibr">104</xref></sup> Another example of the SARS-CoV-2 potential subunit vaccine is the immunogenic virus-like nanoparticles developed by Novavax Company. This type of vaccine is based on the expression of the recombinant SARS-CoV-2-S-protein. Moreover, the Texas Children&#8217;s Hospital Center for Vaccine Development has developed another subunit vaccine against SARS-CoV-2 infection conjugated with alum, which incorporates the receptor-binding domain (RBD) of the viral spike protein.<sup><xref rid="cit0105" ref-type="bibr">105</xref></sup> Although most of these SARS-CoV-2 subunit vaccines are safe and elicit a specific immune response, they trigger low immunogenicity levels. Thus, to overcome this problem and to enhance the effectiveness of most subunit vaccines, immune response-enhancing adjuvant should be considered as in the case of using alum adjuvant above. Meanwhile, specific delivery systems must be convenient to have an optimal response.<sup><xref rid="cit0106" ref-type="bibr">106</xref></sup></p></sec><sec disp-level="1" id="s0016"><title>Some potential SARS-CoV-2 DNA vaccines</title><p>The DNA vaccine technology was well documented and had significant progress in the field of vaccinology of many pathogens, including some other coronaviruses.<sup><xref rid="cit0107" ref-type="bibr">107</xref></sup> Instead of having antigen substances in DNA &#8211; based vaccines, it is better to have a genetic component responsible for antigen production by the host. The DNA vaccines are mimicking natural viral infections. Both of them can trigger the antigen-presenting cells (APCs) to increase the expression of MHC-I as well as the intracellular mediated response via CD8&#160;+&#160;T cells.<sup><xref rid="cit0107" ref-type="bibr">107</xref></sup> Furthermore, the antibody-mediated response was confirmed during the use of DNA vaccines.<sup><xref rid="cit0107" ref-type="bibr">107</xref></sup> To increase the efficacy of the DNA vaccines and to ensure a high delivery of them to the target cells, some components should be mixed with vaccines such as adjuvants, lipid complexes, and micro-particles.<sup><xref rid="cit0108" ref-type="bibr">108</xref></sup> Additionally, the INO-4800 (DNA vaccine) from <italic toggle="yes">in ovo</italic> has developed a vaccine using DNA plasmid encoding SARS-CoV-2-S protein delivered by electroporation. Shenzhen Geno-Immune Medical Institute has also been approved for phase I clinical trials for two vaccine candidates, LV-SMENP-DC and COVID-19 artificial antigen-presenting cells (APC). LV-SMENP-DC is composed of dendritic cells (DCs) modified with a lentiviral vector expressing synthetic mini-genes based on selected viral proteins to activate antigen-specific cytotoxic T cells.<sup><xref rid="cit0088" ref-type="bibr">88</xref></sup></p></sec><sec disp-level="1" id="s0017"><title>The emergence of new SARS-CoV-2 escape mutants and the fine-tuning of the vaccines and vaccination strategies</title><p>Several SARS-CoV-2 mutants were reported recently in many countries, especially the UK, South Africa, Brazil, and India.<sup><xref rid="cit0109" ref-type="bibr">109</xref>,<xref rid="cit0110" ref-type="bibr">110</xref></sup> These mutants have higher transmissibility and replication potential than the viruses reported in the early phase of the pandemic.<sup>109,<xref rid="cit0110" ref-type="bibr">110</xref></sup> Most of these mutations occur within the RBD of the S protein of the virus. These mutations enable the virus to bind firmly to its receptors; the ACE.<sup><xref rid="cit0111" ref-type="bibr">111</xref></sup> These mutants are posing significant risk to human health in many aspects. First, the high replication potentials make these mutants spread much faster in a certain population. Second, these mutants resulted in an increase in the number of hospitalization as well as the number of severe cases. This contributed to the high case fatality rates among the affected populations. Third, some of these mutants escaped the action of neutralizing antibodies generated because of both natural infections with older versions of the virus or antibodies from some vaccinated individuals with some of the recently deployed vaccines.<sup><xref rid="cit0112" ref-type="bibr">112</xref></sup> On the other hand, the new mutants may affect the sensitivity of the already developed diagnostic assays against SARS-CoV-2.<sup><xref rid="cit0113" ref-type="bibr">113</xref></sup> Several studies are recently showing that some of the mRNA-1273 vaccine-based SARS-CoV-2 vaccines may tolerate these escape mutations and are able to induce a potent reduction in the virus infectivity.<sup><xref rid="cit0114" ref-type="bibr">114</xref></sup> We believe the gold standard is the vaccination of the individuals against the homologous strains and variants of the virus is for achieving the required immune response; thus, protection against the natural infection may be granted. Careful and continuous monitoring of the virus is necessary at the current sage to prepare effective vaccines against the most recent circulating strains of the virus.</p></sec><sec disp-level="1" id="s0018"><title>Conclusions</title><p>
The host immune system is one of the key players in the battle against COVID-19. SARS-CoV2 adapts many unique evasion strategies to escape the effects of the host immune responses. The continuous emergence of new viral mutants making the virus several steps ahead of us in its control and mitigation. Through understanding various aspects of SARS-CoV/host immune system interaction, we may unrevealed some novel approaches for its control and prevention. Developments of various types of vaccines and immunotherapeutic are great steps toward the control of SARS-CoV-2. However, careful, and vigilant monitoring of the virus and its evasion strategies are necessary to contain SARS-CoV-2 and put an end to the current pandemic in the near future.</p><p>The virus enters the host cells after an interaction between the spike protein (S) and the ACE-2 host cell receptor in the presence of the TMPRSS2 ligands. The SASR-CoV-2 inhibits the early production of type-I Interferon, including IFN alpha, beta. The antigen-presenting cells (APC), such as macrophages that present antigenic peptides of the virus to the Th0 cells further lead to T cell activation and differentiation to different CD4 T cell subsets (i.e., Th1, Th2, and Th17). The Th1 produces various cytokines such as IFN-gamma, IL-2, and IL-12, which all can activate the CD8 T cells response. The Th2 cells exert their functions via the production of cytokines, including IL-4, IL-5, which activate the B-cell response and result in activation and differentiation into effector plasma cells and memory B cells. This can produce specific neutralizing antibodies against the common SARS-CoV-2 structural proteins, including (S, N, and M) proteins. The SARS-CoV-2 presented by macrophages in combination with MHC-1 will be recognized by CD8 T cells that can produce IFN-gamma, which plays an essential role in the process of viral clearance.</p><p>SARS-CoV-2 can infect the T cells (CD4 and CD8) and lead to a reduction in their total numbers. The pattern recognition receptors, including the Toll-like receptors, can recognize both the extracellular and the intracellular invaded pathogens. The TLR-4 expresses at the surface of airway epithelial cells, macrophages may also recognize the (s) protein, and once the virus releases its genomic RAN material into the cytoplasm during replication. The endoplasmic RNA sensors such as TLR-3, TLR-7, and TLR-8 can further recognize it; this may result in the induction of both the cytokines and the chemokines. Moreover, the infected host cells produce a wide range of pro-inflammatory cytokines and chemokines that also able to recruit several inflammatory cells at the site of infection. The level of their production is associated with the severity of the COVI-19 infection. Thus, the acute respiratory distress syndrome (ARDS) may lead in most cases to the death of the infected individuals; however, some patients may also recover. Red arrows showing inhibitory pathways, while the black arrows indicate an active pathway.</p><p>The virus enters the host cells after an interaction between the spike protein (S) and the ACE-2 host cell receptor in the presence of the TMPRSS2 ligands.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> The SASR-570 inhibits the early production of type-I Interferon, including IFN alpha, beta.<sup><xref rid="cit0115" ref-type="bibr">115</xref></sup> The antigen-presenting cells (APC), such as macrophages that present antigenic peptides of the virus to the Th0 cells that are further lead to T cell activation and differentiation to different CD4 T cell subsets (i.e., Th1, Th2, and Th17).<sup><xref rid="cit0116" ref-type="bibr">116</xref></sup> The Th1 produces various cytokines such as IFN-gamma, IL-2, and IL-12, which all can activate the CD8 T cells response.<sup><xref rid="cit0117" ref-type="bibr">117</xref></sup> The Th2 cells exert their functions via the production of cytokines, including IL-4, IL-5, which activate the B-cell response and result in activation and differentiation into effector plasma cells and memory B cells.<sup><xref rid="cit0112" ref-type="bibr">112</xref></sup> This can produce specific neutralizing antibodies against the common SARS-CoV-2 structural proteins, including (S, N, and M) proteins. The SARS-CoV-2 presented by macrophages in combination with MHC-1 will be recognized 580 by CD8 T cells that can produce IFN-gamma, which plays an essential role in the process of viral clearance. SARS-CoV-2 can infect the T cells (CD4 and CD8) and lead to a reduction in their total numbers.<sup><xref rid="cit0118" ref-type="bibr">118</xref></sup> The pattern recognition receptors, including the Toll-like receptors, can recognize both the extracellular and the intracellular invaded pathogens. The TLR-4 expresses at the surface of airway epithelial cells, macrophages may recognize the (s) protein, and once the virus releases its genomic RAN material into the cytoplasm during replication.<sup><xref rid="cit0119" ref-type="bibr">119</xref></sup> The endoplasmic RNA sensors such as TLR-3, TLR-7, and TLR-8 can further recognize it;<sup><xref rid="cit0120" ref-type="bibr">120</xref></sup> this may result in the induction of both the cytokines and the chemokines. Moreover, the infected host cells produce a wide range of pro-inflammatory cytokines and chemokines that also able to recruit several inflammatory cells at the site of infection. The level of their production is associated with the severity of the COVI-19 infection. Thus, the acute respiratory distress syndrome (ARDS) may lead in most cases to the death of the infected individuals; however, some patients may also recover.<sup><xref rid="cit0121" ref-type="bibr">121</xref></sup> Red arrows showing inhibitory pathways, while the black arrows indicate an active pathway.</p></sec></body><back><sec disp-level="1" id="s0019"><title>Disclosure of potential conflicts of interest</title><p>No potential conflicts of interest were disclosed.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>8</issue>):<fpage>727</fpage>&#8211;<lpage>33</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2001017</pub-id>.<pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Coronaviridae Study Group of the International Committee on Taxonomy of V</collab></person-group>. <article-title>The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title>. <source>Nat Microbiol</source>. <year>2020</year>;<volume>5</volume>:<fpage>536</fpage>&#8211;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41564-020-0695-z</pub-id>.<pub-id pub-id-type="pmid">32123347</pub-id><pub-id pub-id-type="pmcid">PMC7095448</pub-id></mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>WHO</collab></person-group>. <article-title>WHO director-general&#8217;s opening remarks at the media briefing on COVID-19-11 March 2020</article-title>. <year>2020; [accessed&#160;2020&#160;March&#160;11]</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://webarchiveorg/web/20200311212521/https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020" ext-link-type="uri">https://webarchiveorg/web/20200311212521/https://wwwwhoint/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020</ext-link>.</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Xiang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>11</issue>):<fpage>1061</fpage>&#8211;<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id>.<pub-id pub-id-type="pmid">32031570</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Bucci</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Piacentini</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ippolito</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Melino</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>COVID-19 infection: the perspectives on immune responses</article-title>. <source>Cell Death Differ</source>. <year>2020</year>;<volume>27</volume>:<fpage>1451</fpage>&#8211;<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41418-020-0530-3</pub-id>.<pub-id pub-id-type="pmid">32205856</pub-id><pub-id pub-id-type="pmcid">PMC7091918</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ulrich</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Pillat</surname><given-names>MM.</given-names></string-name></person-group><article-title>CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement</article-title>. <source>Stem Cell Rev Rep</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1007/s12015-020-09976-7</pub-id>.<pub-id pub-id-type="pmcid">PMC7167302</pub-id><pub-id pub-id-type="pmid">32307653</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Walls</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Wall</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></string-name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>281</fpage>&#8211;<lpage>92 e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>.<pub-id pub-id-type="pmid">32155444</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Niu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Qiao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></string-name>, et al</person-group>. <article-title>Structural and functional basis of SARS-CoV-2 entry by using human ACE2</article-title>. <source>Cell</source>. <year>2020;181(4):894&#8211;904.e9</year>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.03.045</pub-id>. Epub 2020 Apr 9.<pub-id pub-id-type="pmcid">PMC7144619</pub-id><pub-id pub-id-type="pmid">32275855</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Feng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Qi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title>. <source>Cell Res</source>. <year>2020</year>;<volume>30</volume>:<fpage>343</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41422-020-0305-x</pub-id>.<pub-id pub-id-type="pmid">32231345</pub-id><pub-id pub-id-type="pmcid">PMC7104723</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kruger</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Herrler</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Erichsen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Schiergens</surname><given-names>TS</given-names></string-name>, <string-name name-style="western"><surname>Herrler</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>N-H</given-names></string-name>, <string-name name-style="western"><surname>Nitsche</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>2</issue>):<fpage>271</fpage>&#8211;<lpage>80 e8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id>.<pub-id pub-id-type="pmid">32142651</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bello</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Martinez-Munoz</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Balbuena-Rebolledo</surname><given-names>I</given-names></string-name></person-group>. <article-title>Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA</article-title>. <source>J Mol Model</source>. <year>2020</year>;<volume>26</volume>:<fpage>340</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s00894-020-04600-4</pub-id>.<pub-id pub-id-type="pmid">33184722</pub-id><pub-id pub-id-type="pmcid">PMC7661016</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>YW</given-names></string-name>, <string-name name-style="western"><surname>Yiu</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>KY</given-names></string-name></person-group>. <article-title>Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates</article-title>. <source>F1000Res</source>. <year>2020</year>;<volume>9</volume>:<fpage>129</fpage>. doi:<pub-id pub-id-type="doi">10.12688/f1000research.22457.2</pub-id>.<pub-id pub-id-type="pmid">32194944</pub-id><pub-id pub-id-type="pmcid">PMC7062204</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schoeman</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Fielding</surname><given-names>BC</given-names></string-name></person-group>. <article-title>Coronavirus envelope protein: current knowledge</article-title>. <source>Virol J</source>. <year>2019</year>;<volume>16</volume>:<fpage>69</fpage>.<pub-id pub-id-type="pmid">31133031</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-019-1182-0</pub-id><pub-id pub-id-type="pmcid">PMC6537279</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name></person-group>. <article-title>Coronaviruses: an overview of their replication and pathogenesis</article-title>. <source>Methods Mol Biol</source>. <year>2015</year>;<volume>1282</volume>:<fpage>1</fpage>&#8211;<lpage>23</lpage>.<pub-id pub-id-type="pmid">25720466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id></mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rosendahl Huber</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>van Beek</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>de Jonge</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Luytjes</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>van Baarle</surname><given-names>D</given-names></string-name></person-group>. <article-title>T cell responses to viral infections - opportunities for Peptide vaccination</article-title>. <source>Front Immunol</source>. <year>2014</year>;<volume>5</volume>:<fpage>171</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2014.00171</pub-id>.<pub-id pub-id-type="pmid">24795718</pub-id><pub-id pub-id-type="pmcid">PMC3997009</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murphy</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>C</given-names></string-name></person-group>. <article-title>Janeway&#8217;s immunobiology</article-title>. <source>Garland Sci</source>. <year>2016</year>. ISBN: 978-3-662-56003-7.</mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Zajac</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Harrington</surname><given-names>L</given-names></string-name></person-group>. <part-title>Immune response to viruses: cell-mediated immunity</part-title>. In: <source>Encyclopedia of virology</source>. <publisher-name>Ed Elsevier Ltd</publisher-name>; <year>2008</year>. doi:<pub-id pub-id-type="doi">10.1016/B978-012374410-4.00799-8</pub-id>. Corpus Corpus ID: 81055973.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cecere</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Todd</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Leroith</surname><given-names>T</given-names></string-name></person-group>. <article-title>Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it?</article-title><source>Viruses</source>. <year>2012</year>;<volume>4</volume>:<fpage>833</fpage>&#8211;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.3390/v4050833</pub-id>.<pub-id pub-id-type="pmid">22754651</pub-id><pub-id pub-id-type="pmcid">PMC3386620</pub-id></mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Korn</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bettelli</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Oukka</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kuchroo</surname><given-names>VK</given-names></string-name></person-group>. <article-title>IL-17 and Th17 cells</article-title>. <source>Annu Rev Immunol</source>. <year>2009</year>;<volume>27</volume>:<fpage>485</fpage>&#8211;<lpage>517</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev.immunol.021908.132710</pub-id>.<pub-id pub-id-type="pmid">19132915</pub-id></mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peng</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>D</given-names></string-name></person-group>. <article-title>Broad and strong memory CD4 (+) and CD8 (+) T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients</article-title>. <source>bioRxiv</source>. <year>2020;21(11):1336&#8211;1345</year>. doi:<pub-id pub-id-type="doi">10.1038/s41590-020-0782-6</pub-id>. Epub 2020 Sep 4.<pub-id pub-id-type="pmcid">PMC7611020</pub-id><pub-id pub-id-type="pmid">32887977</pub-id></mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name></person-group>. <article-title>The role of CD4 T cell help for CD8 CTL activation</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2009</year>;<volume>384</volume>:<fpage>405</fpage>&#8211;<lpage>08</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2009.04.134</pub-id>.<pub-id pub-id-type="pmid">19410556</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gupta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Narsai</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Agrawal</surname><given-names>S</given-names></string-name></person-group>. <article-title>SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency</article-title>. <source>Int Arch Allergy Immunol</source>. <year>2021</year>;<volume>182</volume>:<fpage>195</fpage>&#8211;<lpage>209</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000514193</pub-id>.<pub-id pub-id-type="pmid">33486489</pub-id><pub-id pub-id-type="pmcid">PMC7900460</pub-id></mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maloir</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Ghysen</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Louis</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Guiot</surname><given-names>J</given-names></string-name></person-group>. <article-title>Acute respiratory distress revealing antisynthetase syndrome</article-title>. <source>Rev Med Liege</source>. <year>2018</year>;<volume>73</volume>:<fpage>370</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30113776</pub-id></mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Agnihothram</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Fett</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gale</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Baric</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gallagher</surname><given-names>T</given-names></string-name>, et al</person-group>. <article-title>Rapid generation of a mouse model for Middle East respiratory syndrome</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>:<fpage>4970</fpage>&#8211;<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1323279111</pub-id>.<pub-id pub-id-type="pmid">24599590</pub-id><pub-id pub-id-type="pmcid">PMC3977243</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lau</surname><given-names>YF</given-names></string-name>, <string-name name-style="western"><surname>Lamirande</surname><given-names>EW</given-names></string-name>, <string-name name-style="western"><surname>Paddock</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Bartlett</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Zaki</surname><given-names>SR</given-names></string-name>, <string-name name-style="western"><surname>Subbarao</surname><given-names>K</given-names></string-name></person-group>. <article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4<sup>+</sup> T cells are important in control of SARS-CoV infection</article-title>. <source>J Virol</source>. <year>2010</year>;<volume>84</volume>(<issue>3</issue>):<fpage>1289</fpage>&#8211;<lpage>301</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.01281-09</pub-id>.<pub-id pub-id-type="pmid">19906920</pub-id><pub-id pub-id-type="pmcid">PMC2812346</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>CK-F</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Temperton</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>Weiss</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Brenchley</surname><given-names>JM</given-names></string-name>, et al</person-group>. <article-title>T cell responses to whole SARS coronavirus in humans</article-title>. <source>J Immunol</source>. <year>2008</year>;<volume>181</volume>:<fpage>5490</fpage>&#8211;<lpage>500</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.181.8.5490</pub-id>.<pub-id pub-id-type="pmid">18832706</pub-id><pub-id pub-id-type="pmcid">PMC2683413</pub-id></mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>XO</given-names></string-name></person-group>. <article-title>TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib</article-title>. <source>J Microbiol Immunol Infect</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1016/j.jmii.2020.03.005</pub-id>.<pub-id pub-id-type="pmcid">PMC7156211</pub-id><pub-id pub-id-type="pmid">32205092</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mehta</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>McAuley</surname><given-names>DF</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sanchez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tattersall</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Manson</surname><given-names>JJ</given-names></string-name></person-group>. <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>:<fpage>1033</fpage>&#8211;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30628-0</pub-id>.<pub-id pub-id-type="pmid">32192578</pub-id><pub-id pub-id-type="pmcid">PMC7270045</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McGonagle</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sharif</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Regan</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bridgewood</surname><given-names>C</given-names></string-name></person-group>. <article-title>The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease</article-title>. <source>Autoimmun Rev</source>. <year>2020</year>:<fpage>102537</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.autrev.2020.102537</pub-id>.<pub-id pub-id-type="pmid">32251717</pub-id><pub-id pub-id-type="pmcid">PMC7195002</pub-id></mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>KH</given-names></string-name>, <string-name name-style="western"><surname>Effenberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Szpirt</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Kronbichler</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JI</given-names></string-name></person-group>. <article-title>Immunopathogenesis and treatment of cytokine storm in COVID-19</article-title>. <source>Theranostics</source>. <year>2021</year>;<volume>11</volume>:<fpage>316</fpage>&#8211;<lpage>29</lpage>. doi:<pub-id pub-id-type="doi">10.7150/thno.49713</pub-id>.<pub-id pub-id-type="pmid">33391477</pub-id><pub-id pub-id-type="pmcid">PMC7681075</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Xing</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma</article-title>. <source>JAMA</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.4783</pub-id>.<pub-id pub-id-type="pmcid">PMC7101507</pub-id><pub-id pub-id-type="pmid">32219428</pub-id></mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Fan</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Guo</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yi</surname><given-names>Z</given-names></string-name>, et al</person-group>. <article-title>Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)</article-title>. <source>medRxiv</source>. <year>2020</year><month>Feb</month><day>10</day>:<fpage>20021832</fpage>.</mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>XL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>XG</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Si</surname><given-names>H-R</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>C-L</given-names></string-name>, et al</person-group>. <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>. <source>Nature</source>. <year>2020</year>;<volume>579</volume>:<fpage>270</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id>.<pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ng</surname><given-names>O-W</given-names></string-name>, <string-name name-style="western"><surname>Chia</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Jadi</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Leong</surname><given-names>HN</given-names></string-name>, <string-name name-style="western"><surname>Bertoletti</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>Y-J</given-names></string-name></person-group>. <article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title>. <source>Vaccine</source>. <year>2016</year>;<volume>34</volume>:<fpage>2008</fpage>&#8211;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.063</pub-id>.<pub-id pub-id-type="pmid">26954467</pub-id><pub-id pub-id-type="pmcid">PMC7115611</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Dandekar</surname><given-names>AA</given-names></string-name></person-group>. <article-title>Immunopathogenesis of coronavirus infections: implications for SARS</article-title>. <source>Nat Rev Immunol</source>. <year>2005</year>;<volume>5</volume>:<fpage>917</fpage>&#8211;<lpage>27</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri1732</pub-id>.<pub-id pub-id-type="pmid">16322745</pub-id><pub-id pub-id-type="pmcid">PMC7097326</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, et al</person-group>. <article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title>. <source>Lancet Respir Med</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30076-X</pub-id>.<pub-id pub-id-type="pmcid">PMC7164771</pub-id><pub-id pub-id-type="pmid">32085846</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>Y-S</given-names></string-name>, <string-name name-style="western"><surname>Lian</surname><given-names>J-Q</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Geng</surname><given-names>JJ</given-names></string-name>, et al</person-group>. <article-title>SARS-CoV-2 invades host cells via a novel route: CD147-spike protein</article-title>. <source>bioRxiv</source>. <year>2020</year> Dec <day>4;5(1):283</day>. doi:<pub-id pub-id-type="doi">10.1038/s41392-020-00426-x</pub-id>.<pub-id pub-id-type="pmcid">PMC7714896</pub-id><pub-id pub-id-type="pmid">33277466</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shin</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Jeong</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Joh</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>J-S</given-names></string-name>, et al</person-group>. <article-title>Immune responses to middle east respiratory syndrome coronavirus during the acute and convalescent phases of human infection</article-title>. <source>Clin Infect Dis</source>. <year>2019</year>;<volume>68</volume>:<fpage>984</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/ciy595</pub-id>.<pub-id pub-id-type="pmid">30060038</pub-id><pub-id pub-id-type="pmcid">PMC7108191</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mangalam</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Channappanavar</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fett</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Agnihothram</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Baric</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>David</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses</article-title>. <source>Immunity</source>. <year>2016</year>;<volume>44</volume>:<fpage>1379</fpage>&#8211;<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2016.05.006</pub-id>.<pub-id pub-id-type="pmid">27287409</pub-id><pub-id pub-id-type="pmcid">PMC4917442</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wrapp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>De Vlieger</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Corbett</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Torres</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Van Breedam</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Roose</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>van Schie</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>P&#246;hlmann</surname><given-names>S</given-names></string-name>, et al</person-group>. <article-title>Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies</article-title>. <source>Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>5</issue>):<fpage>1004</fpage>&#8211;<lpage>15 e15</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.04.031</pub-id>.<pub-id pub-id-type="pmid">32375025</pub-id><pub-id pub-id-type="pmcid">PMC7199733</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cromer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Juno</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Khoury</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Reynaldi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wheatley</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Kent</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Davenport</surname><given-names>MP</given-names></string-name></person-group>. <article-title>Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection</article-title>. <source>Nat Rev Immunol</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1038/s41577-021-00550-x</pub-id>.<pub-id pub-id-type="pmcid">PMC8082486</pub-id><pub-id pub-id-type="pmid">33927374</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Haveri</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Smura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kuivanen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>&#214;sterlund</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Hepojoki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ikonen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pitk&#228;paasi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Blomqvist</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>R&#246;nkk&#246;</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kantele</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020</article-title>. <source>Euro Surveill</source>. <year>2020</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2000266</fpage>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.11.2000266</pub-id>.<pub-id pub-id-type="pmcid">PMC7096774</pub-id><pub-id pub-id-type="pmid">32209163</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>R-H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>X-S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X-L</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>-Y-Y</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>G-F</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>Z-L</given-names></string-name>, et al</person-group>. <article-title>Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes</article-title>. <source>Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>386</fpage>&#8211;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1080/22221751.2020.1729071</pub-id>.<pub-id pub-id-type="pmid">32065057</pub-id><pub-id pub-id-type="pmcid">PMC7048229</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Le</surname><given-names>X</given-names></string-name></person-group>. <article-title>Serology of severe acute respiratory syndrome: implications for surveillance and outcome</article-title>. <source>J Infect Dis</source>. <year>2004</year>;<volume>189</volume>(<issue>7</issue>):<fpage>1158</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.1086/380397</pub-id>.<pub-id pub-id-type="pmid">15031782</pub-id><pub-id pub-id-type="pmcid">PMC7110198</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bao</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xiao</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Reinfection could not occur in SARS-CoV-2 infected rhesus macaques</article-title>. <source>bioRxiv</source>. <year>2020</year><month>Mar</month><day>13</day>:<fpage>990226</fpage>. doi:<pub-id pub-id-type="doi">10.1101/2020.03.13.990226</pub-id>.</mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></string-name></person-group>. <article-title>Pirofski L-a. The convalescent sera option for containing COVID-19</article-title>. <source>J Clin Invest</source>. <year>2020</year>;<volume>130</volume>:<fpage>1545</fpage>&#8211;<lpage>48</lpage>.<pub-id pub-id-type="pmid">32167489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI138003</pub-id><pub-id pub-id-type="pmcid">PMC7108922</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Duan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Meng</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title>. <source>Proc Nat Acad Sci</source>. <year>2020Apr 28;117(17):9490&#8211;9496</year>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmcid">PMC7196837</pub-id><pub-id pub-id-type="pmid">32253318</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wang</surname><given-names>S-F</given-names></string-name>, <string-name name-style="western"><surname>Tseng</surname><given-names>S-P</given-names></string-name>, <string-name name-style="western"><surname>Yen</surname><given-names>C-H</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>J-Y</given-names></string-name>, <string-name name-style="western"><surname>Tsao</surname><given-names>C-H</given-names></string-name>, <string-name name-style="western"><surname>Shen</surname><given-names>C-W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>K-H</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>F-T</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>W-T</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YMA</given-names></string-name>, et al</person-group>. <article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2014</year>;<volume>451</volume>(<issue>2</issue>):<fpage>208</fpage>&#8211;<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2014.07.090</pub-id>.<pub-id pub-id-type="pmid">25073113</pub-id><pub-id pub-id-type="pmcid">PMC7092860</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shanmugaraj</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Siriwattananon</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Wangkanont</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Phoolcharoen</surname><given-names>W</given-names></string-name></person-group>. <article-title>Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)</article-title>. <source>Asian Pac J Allergy Immunol</source>. <year>2020</year>;<volume>38</volume>:<fpage>10</fpage>&#8211;<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.12932/AP-200220-0773</pub-id>.<pub-id pub-id-type="pmid">32134278</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hartley</surname><given-names>GE</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>ESJ</given-names></string-name>, <string-name name-style="western"><surname>Aui</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Varese</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Stojanovic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McMahon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Peleg</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Boo</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Drummer</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Hogarth</surname><given-names>PM</given-names></string-name>, et al</person-group>. <article-title>Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence</article-title>. <source>Sci Immunol</source>. <year>2020</year>;<volume>5</volume>(<issue>54</issue>):<fpage>eabf8891</fpage>. doi:<pub-id pub-id-type="doi">10.1126/sciimmunol.abf8891</pub-id>.<pub-id pub-id-type="pmid">33443036</pub-id><pub-id pub-id-type="pmcid">PMC7877496</pub-id></mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dan</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Mateus</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kato</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Hastie</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Yu</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Faliti</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Haupt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Frazier</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection</article-title>. <source>Science</source>. <year>2021</year>;<volume>371</volume>:<fpage>eabf4063</fpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abf4063</pub-id>.<pub-id pub-id-type="pmid">33408181</pub-id><pub-id pub-id-type="pmcid">PMC7919858</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sosa-Hern&#225;ndez</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Torres-Ru&#237;z</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Cervantes-D&#237;az</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Romero-Ram&#237;rez</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>P&#225;ez-Franco</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Meza-S&#225;nchez</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Ju&#225;rez-Vega</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez-Fragoso</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ortiz-Navarrete</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ponce-de-Le&#243;n</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>B cell subsets as severity-associated signatures in COVID-19 patients</article-title>. <source>Front Immunol</source>. <year>2020</year>:<fpage>11</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.611004</pub-id>.<pub-id pub-id-type="pmid">33343585</pub-id><pub-id pub-id-type="pmcid">PMC7744304</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mathew</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Giles</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Baxter</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Oldridge</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Greenplate</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Alanio</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kuri-Cervantes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><given-names>Pampena</given-names><surname>MB</surname></string-name>, <string-name name-style="western"><surname>D&#8217;Andrea</surname><given-names>K</given-names></string-name>, et al</person-group>. <article-title>Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>:<fpage>eabc8511</fpage>.<pub-id pub-id-type="pmid">32669297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc8511</pub-id><pub-id pub-id-type="pmcid">PMC7402624</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Oliviero</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Varchetta</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mele</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mantovani</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cerino</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Perotti</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Ludovisi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mondelli</surname><given-names>MU</given-names></string-name></person-group>. <article-title>Expansion of atypical memory B cells is a prominent feature of COVID-19</article-title>. <source>Cell Mol Immunol</source>. <year>2020</year>;<volume>17</volume>:<fpage>1101</fpage>&#8211;<lpage>03</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41423-020-00542-2</pub-id>.<pub-id pub-id-type="pmid">32879471</pub-id><pub-id pub-id-type="pmcid">PMC7463104</pub-id></mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mubarak</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Alturaiki</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Hemida</surname><given-names>MG</given-names></string-name></person-group>. <article-title>Middle east respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development</article-title>. <source>J Immunol Res</source>. <year>2019</year>;<volume>2019</volume>:<fpage>6491738</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2019/6491738</pub-id>.<pub-id pub-id-type="pmid">31089478</pub-id><pub-id pub-id-type="pmcid">PMC6476043</pub-id></mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dong</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Qu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Qiu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>507</fpage>&#8211;<lpage>13</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id>.<pub-id pub-id-type="pmid">32007143</pub-id><pub-id pub-id-type="pmcid">PMC7135076</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Snijder</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>van der Meer</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zevenhoven-Dobbe</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Onderwater</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>van der Meulen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Koerten</surname><given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Mommaas</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex</article-title>. <source>J Virol</source>. <year>2006</year>;<volume>80</volume>(<issue>12</issue>):<fpage>5927</fpage>&#8211;<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.02501-05</pub-id>.<pub-id pub-id-type="pmid">16731931</pub-id><pub-id pub-id-type="pmcid">PMC1472606</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Niemeyer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zillinger</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Muth</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zielecki</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Horvath</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Suliman</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Barchet</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Drosten</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Muller</surname><given-names>MA</given-names></string-name>, et al</person-group>. <article-title>Middle East respiratory syndrome coronavirus accessory protein 4a is a type I interferon antagonist</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>22</issue>):<fpage>12489</fpage>&#8211;<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.01845-13</pub-id>.<pub-id pub-id-type="pmid">24027320</pub-id><pub-id pub-id-type="pmcid">PMC3807936</pub-id></mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Schafer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Burnum-Johnson</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Eisfeld</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Walters</surname><given-names>KB</given-names></string-name>, <string-name name-style="western"><surname>Nicora</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Purvine</surname><given-names>SO</given-names></string-name>, <string-name name-style="western"><surname>Casey</surname><given-names>CP</given-names></string-name>, <string-name name-style="western"><surname>Monroe</surname><given-names>ME</given-names></string-name>, et al</person-group>. <article-title>MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>5</issue>):<fpage>E1012</fpage>&#8211;<lpage>E21</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1706928115</pub-id>.<pub-id pub-id-type="pmid">29339515</pub-id><pub-id pub-id-type="pmcid">PMC5798318</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Canton</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fehr</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Fernandez-Delgado</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Sanchez-Aparicio</surname><given-names>MT</given-names></string-name>, <string-name name-style="western"><surname>Garcia-Sastre</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Perlman</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Enjuanes</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Sola</surname><given-names>I</given-names></string-name></person-group>. <article-title>MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection</article-title>. <source>PLoS Pathog</source>. <year>2018</year>;<volume>14</volume>:<fpage>e1006838</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1006838</pub-id>.<pub-id pub-id-type="pmid">29370303</pub-id><pub-id pub-id-type="pmcid">PMC5800688</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>XB</given-names></string-name></person-group>. <article-title>Persistent viral RNA positivity during recovery period of a patient with SARS-CoV-2 infection</article-title>. <source>J Med Virol</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1002/jmv.25940</pub-id>.<pub-id pub-id-type="pmcid">PMC7264719</pub-id><pub-id pub-id-type="pmid">32330293</pub-id></mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thoms</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Buschauer</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ameismeier</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Koepke</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Denk</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Hirschenberger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kratzat</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hayn</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mackens-Kiani</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2</article-title>. <source>Science</source>. <year>2020</year>;<volume>369</volume>:<fpage>1249</fpage>&#8211;<lpage>55</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abc8665</pub-id>.<pub-id pub-id-type="pmid">32680882</pub-id><pub-id pub-id-type="pmcid">PMC7402621</pub-id></mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Menachery</surname><given-names>VD</given-names></string-name>, <string-name name-style="western"><surname>Rajsbaum</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>P-Y</given-names></string-name></person-group>. <article-title>Evasion of type i interferon by SARS-CoV-2</article-title>. <source>Cell Rep</source>. <year>2020</year>;<volume>33</volume>(<issue>1</issue>):<fpage>108234</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.celrep.2020.108234</pub-id>.<pub-id pub-id-type="pmid">32979938</pub-id><pub-id pub-id-type="pmcid">PMC7501843</pub-id></mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shin</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Mukherjee</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Grewe</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bojkova</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Baek</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Bhattacharya</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schulz</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Widera</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Mehdipour</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Tascher</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity</article-title>. <source>Nature</source>. <year>2020</year>;<volume>587</volume>(<issue>7835</issue>):<fpage>657</fpage>&#8211;<lpage>62</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2601-5</pub-id>.<pub-id pub-id-type="pmid">32726803</pub-id><pub-id pub-id-type="pmcid">PMC7116779</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vithani</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ward</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Zimmerman</surname><given-names>MI</given-names></string-name>, <string-name name-style="western"><surname>Novak</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Borowsky</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bowman</surname><given-names>GR</given-names></string-name></person-group>. <article-title>SARS-CoV-2 Nsp16 activation mechanism and a cryptic pocket with pan-coronavirus antiviral potential</article-title>. <source>Biophys J</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1016/j.bpj.2021.03.024</pub-id>.<pub-id pub-id-type="pmcid">PMC8007187</pub-id><pub-id pub-id-type="pmid">33794150</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Majumdar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Niyogi</surname><given-names>S</given-names></string-name></person-group>. <article-title>ORF3a mutation associated with higher mortality rate in SARS-CoV-2 infection</article-title>. <source>Epidemiol Infect</source>. <year>2020</year>;<volume>148</volume>:<fpage>e262</fpage>. doi:<pub-id pub-id-type="doi">10.1017/S0950268820002599</pub-id>.<pub-id pub-id-type="pmid">33100263</pub-id><pub-id pub-id-type="pmcid">PMC7653495</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zinzula</surname><given-names>L</given-names></string-name></person-group>. <article-title>Lost in deletion: the enigmatic ORF8 protein of SARS-CoV-2</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2021</year>;<volume>538</volume>:<fpage>116</fpage>&#8211;<lpage>24</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbrc.2020.10.045</pub-id>.<pub-id pub-id-type="pmid">33685621</pub-id><pub-id pub-id-type="pmcid">PMC7577707</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramirez Hernandez</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Hernandez-Zimbron</surname><given-names>LF</given-names></string-name>, <string-name name-style="western"><surname>Martinez Zuniga</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Leal-Garcia</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Ignacio Hernandez</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Ucharima-Corona</surname><given-names>LE</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez Campos</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zenteno</surname><given-names>E</given-names></string-name></person-group>. <article-title>The role of the SARS-CoV-2 S-protein glycosylation in the Interaction of SARS-CoV-2/ACE2 and immunological responses</article-title>. <source>Viral Immunol</source>. <year>2021</year>;<volume>34</volume>:<fpage>165</fpage>&#8211;<lpage>73</lpage>. doi:<pub-id pub-id-type="doi">10.1089/vim.2020.0174</pub-id>.<pub-id pub-id-type="pmid">33605822</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname><given-names>S</given-names></string-name></person-group>. <article-title>The structure of the membrane protein of SARS-CoV-2 resembles the sugar transporter SemiSWEET</article-title>. <source>Pathog Immun</source>. <year>2020</year>;<volume>5</volume>:<fpage>342</fpage>&#8211;<lpage>63</lpage>. doi:<pub-id pub-id-type="doi">10.20411/pai.v5i1.377</pub-id>.<pub-id pub-id-type="pmid">33154981</pub-id><pub-id pub-id-type="pmcid">PMC7608487</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsybovsky</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Gorman</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rapp</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Cerutti</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chuang</surname><given-names>G-Y</given-names></string-name>, <string-name name-style="western"><surname>Katsamba</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Sampson</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Sch&#246;n</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bimela</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>Cryo-EM structures of SARS-CoV-2 spike without and with ACE2 reveal a pH-dependent switch to mediate endosomal positioning of receptor-binding domains</article-title>. <source>Cell Host Microbe</source>. <year>2020</year>;<volume>28</volume>(<issue>6</issue>):<fpage>867</fpage>&#8211;<lpage>79 e5</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2020.11.004</pub-id>.<pub-id pub-id-type="pmid">33271067</pub-id><pub-id pub-id-type="pmcid">PMC7670890</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>F</given-names></string-name></person-group>. <article-title>SARS-CoV-2 ORF9c: a mysterious membrane-anchored protein that regulates immune evasion?</article-title><source>Nat Rev Immunol</source>. <year>2020</year>;<volume>20</volume>:<fpage>648</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41577-020-00449-z</pub-id>.<pub-id pub-id-type="pmcid">PMC7475951</pub-id><pub-id pub-id-type="pmid">32895512</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Khan</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Jha</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Amera</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Muthukumaran</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>AK</given-names></string-name></person-group>. <article-title>Identification of promising antiviral drug candidates against non-structural protein 15 (NSP15) from SARS-CoV-2: an in silico assisted drug-repurposing study</article-title>. <source>J Biomol Struct Dyn</source>. <year>2020</year>:<fpage>1</fpage>&#8211;<lpage>11</lpage>. doi:<pub-id pub-id-type="doi">10.1080/07391102.2020.1814870</pub-id>.<pub-id pub-id-type="pmid">32885740</pub-id></mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="report"><person-group person-group-type="author"><collab>DrugBank</collab></person-group>. <article-title>ChAdOx1 nCoV-19</article-title>; <year>2020</year>.</mixed-citation></ref><ref id="cit0074"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Bittaye</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>FR</given-names></string-name>, <string-name name-style="western"><surname>Bellamy</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Kupke</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mair</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Makinson</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sheridan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rohde</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title>. <source>Lancet Infect Dis</source>. <year>2020</year>;<volume>20</volume>(<issue>7</issue>):<fpage>816</fpage>&#8211;<lpage>26</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30160-2</pub-id>.<pub-id pub-id-type="pmid">32325038</pub-id><pub-id pub-id-type="pmcid">PMC7172901</pub-id></mixed-citation></ref><ref id="cit0075"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Prompetchara</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Ketloy</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Palaga</surname><given-names>T</given-names></string-name></person-group>. <article-title>Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic</article-title>. <source>Asian Pac J Allergy Immunol</source>. <year>2020</year>;<volume>38</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.12932/AP-200220-0772</pub-id>.<pub-id pub-id-type="pmid">32105090</pub-id></mixed-citation></ref><ref id="cit0076"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lu</surname><given-names>S</given-names></string-name></person-group>. <article-title>Timely development of vaccines against SARS-CoV-2</article-title>. <source>Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>:<fpage>542</fpage>&#8211;<lpage>44</lpage>. doi:<pub-id pub-id-type="doi">10.1080/22221751.2020.1737580</pub-id>.<pub-id pub-id-type="pmid">32148172</pub-id><pub-id pub-id-type="pmcid">PMC7144304</pub-id></mixed-citation></ref><ref id="cit0077"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Polack</surname><given-names>FP</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Absalon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Perez</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Moreira</surname><given-names>ED</given-names></string-name>, <string-name name-style="western"><surname>Zerbini</surname><given-names>C</given-names></string-name>, et al</person-group>. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>383</volume>(<issue>27</issue>):<fpage>2603</fpage>&#8211;<lpage>15</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id>.<pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></mixed-citation></ref><ref id="cit0078"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Soiza</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Scicluna</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Thomson</surname><given-names>EC</given-names></string-name></person-group>. <article-title>Efficacy and safety of COVID-19 vaccines in older people</article-title>. <source>Age Ageing</source>. <year>2021</year>;<volume>50</volume>(<issue>2</issue>):<fpage>279</fpage>&#8211;<lpage>83</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ageing/afaa274</pub-id>.<pub-id pub-id-type="pmid">33320183</pub-id><pub-id pub-id-type="pmcid">PMC7799251</pub-id></mixed-citation></ref><ref id="cit0079"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Voysey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Clemens</surname><given-names>SAC</given-names></string-name>, <string-name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Aley</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Angus</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baillie</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Barnabas</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Bhorat</surname><given-names>QE</given-names></string-name>, et al</person-group>. <article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10269</issue>):<fpage>99</fpage>&#8211;<lpage>111</lpage>.<pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></mixed-citation></ref><ref id="cit0080"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></string-name>, <string-name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></string-name>, <string-name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></string-name>, <string-name name-style="western"><surname>Tukhvatulin</surname><given-names>AI</given-names></string-name>, <string-name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></string-name>, <string-name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Kovyrshina</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Lubenets</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Grousova</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Erokhova</surname><given-names>AS</given-names></string-name>, et al</person-group>. <article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10275</issue>):<fpage>671</fpage>&#8211;<lpage>81</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00234-8</pub-id>.<pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></mixed-citation></ref><ref id="cit0081"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Le Gars</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shukarev</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Heerwegh</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Truyers</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>de Groot</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Stoop</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Tete</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Van Damme</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Leroux-Roels</surname><given-names>I</given-names></string-name>, et al</person-group>. <article-title>Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine</article-title>. <source>N Engl J Med</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2034201</pub-id>.<pub-id pub-id-type="pmcid">PMC7821985</pub-id><pub-id pub-id-type="pmid">33440088</pub-id></mixed-citation></ref><ref id="cit0082"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Roy</surname><given-names>P</given-names></string-name></person-group>. <article-title>Sputnik V COVID-19 vaccine candidate appears safe and effective</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>(<issue>10275</issue>):<fpage>642</fpage>&#8211;<lpage>43</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00191-4</pub-id>.<pub-id pub-id-type="pmid">33545098</pub-id><pub-id pub-id-type="pmcid">PMC7906719</pub-id></mixed-citation></ref><ref id="cit0083"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Palacios</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Patino</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>de Oliveira Piorelli</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Conde</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Batista</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xin</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Kallas</surname><given-names>EG</given-names></string-name>, <string-name name-style="western"><surname>Flores</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ockenhouse</surname><given-names>CF</given-names></string-name>, et al</person-group>. <article-title>Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (Inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial</article-title>. <source>Trials</source>. <year>2020</year>;<volume>21</volume>(<issue>1</issue>):<fpage>853</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13063-020-04775-4</pub-id>.<pub-id pub-id-type="pmid">33059771</pub-id><pub-id pub-id-type="pmcid">PMC7558252</pub-id></mixed-citation></ref><ref id="cit0084"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xia</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Duan</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>324</volume>(<issue>10</issue>):<fpage>951</fpage>&#8211;<lpage>60</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.15543</pub-id>.<pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></mixed-citation></ref><ref id="cit0085"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mahase</surname><given-names>E</given-names></string-name></person-group>. <article-title>Covid-19: novavax vaccine efficacy is 86% against UK variant and 60% against South African variant</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>372</volume>:<fpage>n296</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n296</pub-id>.<pub-id pub-id-type="pmid">33526412</pub-id></mixed-citation></ref><ref id="cit0086"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Guan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>J</given-names></string-name>, et al</person-group>. <article-title>COVID-19: coronavirus vaccine development updates</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>602256</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2020.602256</pub-id>.<pub-id pub-id-type="pmid">33424848</pub-id><pub-id pub-id-type="pmcid">PMC7785583</pub-id></mixed-citation></ref><ref id="cit0087"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garg</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mehmetoglu-Gurbuz</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Joshi</surname><given-names>A</given-names></string-name></person-group>. <article-title>Recent advances in zika virus vaccines</article-title>. <source>Viruses</source>. <year>2018</year>:<fpage>10</fpage>. doi:<pub-id pub-id-type="doi">10.3390/v10110631</pub-id>.<pub-id pub-id-type="pmcid">PMC6267279</pub-id><pub-id pub-id-type="pmid">30441757</pub-id></mixed-citation></ref><ref id="cit0088"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>van Doremalen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lambe</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Purushotham</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Port</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Avanzato</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Bushmaker</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Flaxman</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ulaszewska</surname><given-names>M</given-names></string-name>, et al</person-group>. <article-title>ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>. Nature. <year>2020 Oct;586(7830):578&#8211;582</year>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2608-y</pub-id>. Epub 2020 Jul 30.<pub-id pub-id-type="pmcid">PMC8436420</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></mixed-citation></ref><ref id="cit0089"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Baden</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Essink</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Frey</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Novak</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Diemert</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Spector</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Rouphael</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Creech</surname><given-names>CB</given-names></string-name>, et al</person-group>. <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>N Engl J Med</source>. <year>2021</year>;<volume>384</volume>:<fpage>403</fpage>&#8211;<lpage>16</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id>.<pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></mixed-citation></ref><ref id="cit0090"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meyer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>GR</given-names></string-name>, <string-name name-style="western"><surname>Rubenstein</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Ramanathan</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Mire</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Pietzsch</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Ge</surname><given-names>Y</given-names></string-name>, et al</person-group>. <article-title>mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge</article-title>. <source>bioRxiv</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1101/2021.01.25.428136</pub-id>.<pub-id pub-id-type="pmcid">PMC8516449</pub-id><pub-id pub-id-type="pmid">34449440</pub-id></mixed-citation></ref><ref id="cit0091"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Voysey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Costa Clemens</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></string-name>, <string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Aley</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Angus</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Baillie</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Barnabas</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Bhorat</surname><given-names>QE</given-names></string-name>, et al</person-group>. <article-title>Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>397</volume>:<fpage>881</fpage>&#8211;<lpage>91</lpage>.<pub-id pub-id-type="pmid">33617777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00432-3</pub-id><pub-id pub-id-type="pmcid">PMC7894131</pub-id></mixed-citation></ref><ref id="cit0092"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ramasamy</surname><given-names>MN</given-names></string-name>, <string-name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Flaxman</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Owens</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Voysey</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Aley</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Angus</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Babbage</surname><given-names>G</given-names></string-name>, et al</person-group>. <article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial</article-title>. <source>Lancet</source>. <year>2021</year>;<volume>396</volume>:<fpage>1979</fpage>&#8211;<lpage>93</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)32466-1</pub-id>.<pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></mixed-citation></ref><ref id="cit0093"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahmed</surname><given-names>SF</given-names></string-name>, <string-name name-style="western"><surname>Quadeer</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>McKay</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies</article-title>. <source>Viruses</source>. <year>2020</year>:<fpage>12</fpage>. doi:<pub-id pub-id-type="doi">10.3390/v12030254</pub-id>.<pub-id pub-id-type="pmcid">PMC7150947</pub-id><pub-id pub-id-type="pmid">32106567</pub-id></mixed-citation></ref><ref id="cit0094"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dhama</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Sharun</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Dadar</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Malik</surname><given-names>YS</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>KP</given-names></string-name>, <string-name name-style="western"><surname>Chaicumpa</surname><given-names>W</given-names></string-name></person-group>. <article-title>COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics</article-title>. <source>Hum Vaccin Immunother</source>. <year>2020Jun 2;16(6):1232&#8211;1238</year>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2020.1735227</pub-id>. Epub 2020 Mar 18.<pub-id pub-id-type="pmcid">PMC7103671</pub-id><pub-id pub-id-type="pmid">32186952</pub-id></mixed-citation></ref><ref id="cit0095"><label>95.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Shieber</surname><given-names>J.</given-names></string-name></person-group><article-title>Codagenix raises $20 million for a new flu vaccine and other therapies</article-title>. <publisher-name>Tech Crunch</publisher-name>; [<comment>accessed</comment><year>2020</year><month>Feb</month><day>28</day>]. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://techcrunchcom/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-other-therapies/" ext-link-type="uri">https://techcrunchcom/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-other-therapies/</ext-link>. <comment>Return to ref 23 in article 2020</comment>.</mixed-citation></ref><ref id="cit0096"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Plotkin</surname><given-names>S</given-names></string-name></person-group>. <article-title>Vaccines: correlates of vaccine-induced immunity</article-title>. <source>Clin Infect Dis</source>. <year>2008</year>;<volume>47</volume>:<fpage>401</fpage>&#8211;<lpage>09</lpage>. doi:<pub-id pub-id-type="doi">10.1086/589862</pub-id>.<pub-id pub-id-type="pmid">18558875</pub-id></mixed-citation></ref><ref id="cit0097"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Qiang</surname><given-names>GLB</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Lv</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Rapid development of an inactivated vaccine for SARS-CoV-2</article-title>. Science. <year>2020 Jul 3;369(6499):77&#8211;81</year>. doi:<pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>. Epub 2020 May 6.<pub-id pub-id-type="pmcid">PMC7202686</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="cit0098"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zverev</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Katlinskii</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Kostinov</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Zhirova</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Erofeeva</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Stukova</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Korovkin</surname><given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Mel&#8217;nikov</surname><given-names>SI</given-names></string-name>, <string-name name-style="western"><surname>Semchenko</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Mironov</surname><given-names>AN</given-names></string-name>, et al</person-group>. <article-title>Comparative clinical trial of vaccines against avian influenza</article-title>. <source>Zh Mikrobiol Epidemiol Immunobiol</source>. <year>2007;(3):10&#8211;6</year>.<pub-id pub-id-type="pmid">17672124</pub-id></mixed-citation></ref><ref id="cit0099"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>ZN</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>YY</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname><given-names>HD</given-names></string-name>, <string-name name-style="western"><surname>Cai</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>XX</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>FS</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>YN</given-names></string-name>, <string-name name-style="western"><surname>Shu</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Evaluation of safety of two inactivated COVID-19 vaccines in a large-scale emergency use</article-title>. <source>Zhonghua Liu Xing Bing Xue Za Zhi</source>. <year>2021</year>;<volume>42</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.3760/cma.j.cn112338-20210325-00249</pub-id>.<pub-id pub-id-type="pmid">33874701</pub-id></mixed-citation></ref><ref id="cit0100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Pan</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yin</surname><given-names>W</given-names></string-name>, et al</person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis</source>. <year>2021</year>;<volume>21</volume>:<fpage>181</fpage>&#8211;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30843-4</pub-id>.<pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></mixed-citation></ref><ref id="cit0101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hemida</surname><given-names>MG</given-names></string-name>, <string-name name-style="western"><surname>Ba Abduallah</surname><given-names>MM</given-names></string-name></person-group>. <article-title>The SARS-CoV-2 outbreak from a one health perspective</article-title>. <source>One Health</source>. <year>2020</year>:<fpage>100127</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.onehlt.2020.100127</pub-id>.<pub-id pub-id-type="pmid">32292814</pub-id><pub-id pub-id-type="pmcid">PMC7102578</pub-id></mixed-citation></ref><ref id="cit0102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>S</given-names></string-name></person-group>. <article-title>Receptor-binding domain as a target for developing SARS vaccines</article-title>. <source>J Thorac Dis</source>. <year>2013</year>:<fpage>S142</fpage>&#8211;<lpage>S8</lpage>. doi:<pub-id pub-id-type="doi">10.3978/j.2072-1439.2013.06.06</pub-id>.<pub-id pub-id-type="pmid">23977435</pub-id><pub-id pub-id-type="pmcid">PMC3747534</pub-id></mixed-citation></ref><ref id="cit0103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>MX</given-names></string-name>, <string-name name-style="western"><surname>Ang</surname><given-names>IYH</given-names></string-name>, <string-name name-style="western"><surname>Tan</surname><given-names>SHX</given-names></string-name>, <string-name name-style="western"><surname>Lewis</surname><given-names>RF</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Gutierrez</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Gwee</surname><given-names>SXW</given-names></string-name>, <string-name name-style="western"><surname>Chua</surname><given-names>PEY</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>Q</given-names></string-name>, et al</person-group>. <article-title>Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review</article-title>. <source>J Clin Med</source>. <year>2020</year>:<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.3390/jcm9030623</pub-id>.<pub-id pub-id-type="pmcid">PMC7141113</pub-id><pub-id pub-id-type="pmid">32110875</pub-id></mixed-citation></ref><ref id="cit0104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biopharmaceuticals</surname><given-names>C</given-names></string-name></person-group>. <article-title>Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV)</article-title>. <year>2020</year>:<fpage>2020</fpage>. AP news Press release,01/28/2020, avaliable at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://apnews.com/press-release/pr-businesswire/fe24e251ddb843a9b091561a06f8eead" ext-link-type="uri">https://apnews.com/press-release/pr-businesswire/fe24e251ddb843a9b091561a06f8eead</ext-link></mixed-citation></ref><ref id="cit0105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Mao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Su</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Gong</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Du</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>X</given-names></string-name>, et al</person-group>. <article-title>Site-specific N-glycosylation characterization of recombinant SARS-CoV-2 spike proteins</article-title>. <source>Mol Cell Proteomics</source>. <year>2021</year>;<volume>20</volume>:<fpage>100058</fpage>. doi:<pub-id pub-id-type="doi">10.1074/mcp.RA120.002295</pub-id>.<pub-id pub-id-type="pmcid">PMC7876485</pub-id><pub-id pub-id-type="pmid">33077685</pub-id></mixed-citation></ref><ref id="cit0106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>MacLeod</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kappler</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marrack</surname><given-names>P</given-names></string-name></person-group>. <article-title>Immune mechanisms of protection: can adjuvants rise to the challenge?</article-title><source>BMC Biol</source>. <year>2010</year>;<volume>8</volume>:<fpage>37</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1741-7007-8-37</pub-id>.<pub-id pub-id-type="pmid">20385031</pub-id><pub-id pub-id-type="pmcid">PMC2864095</pub-id></mixed-citation></ref><ref id="cit0107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Donnelly</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Wahren</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>MA</given-names></string-name></person-group>. <article-title>DNA vaccines: progress and challenges</article-title>. <source>J Immunol</source>. <year>2005</year>;<volume>175</volume>:<fpage>633</fpage>&#8211;<lpage>39</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.175.2.633</pub-id>.<pub-id pub-id-type="pmid">16002657</pub-id></mixed-citation></ref><ref id="cit0108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ferraro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Morrow</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Hutnick</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Lucke</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Weiner</surname><given-names>DB</given-names></string-name></person-group>. <article-title>Clinical applications of DNA vaccines: current progress</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>53</volume>:<fpage>296</fpage>&#8211;<lpage>302</lpage>. doi:<pub-id pub-id-type="doi">10.1093/cid/cir334</pub-id>.<pub-id pub-id-type="pmid">21765081</pub-id><pub-id pub-id-type="pmcid">PMC3202319</pub-id></mixed-citation></ref><ref id="cit0109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yuan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CD</given-names></string-name>, <string-name name-style="western"><surname>Wu</surname><given-names>NC</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Peng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>van Gils</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Sanders</surname><given-names>RW</given-names></string-name>, et al</person-group>. <article-title>Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants</article-title>. <source>bioRxiv</source>. <year>2021 May 20;eabh1139</year>. doi:<pub-id pub-id-type="doi">10.1126/science.abh1139</pub-id>.<pub-id pub-id-type="pmcid">PMC8284396</pub-id><pub-id pub-id-type="pmid">34016740</pub-id></mixed-citation></ref><ref id="cit0110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhou</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Dejnirattisai</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Supasa</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Mentzer</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Ginn</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Duyvesteyn</surname><given-names>HME</given-names></string-name>, <string-name name-style="western"><surname>Tuekprakhon</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Nutalai</surname><given-names>R</given-names></string-name>, et al</person-group>. <article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>. <source>Cell</source>. <year>2021</year>;<volume>184</volume>(<issue>9</issue>):<fpage>2348</fpage>&#8211;<lpage>2361.e6</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2021.02.037</pub-id>.<pub-id pub-id-type="pmid">33730597</pub-id><pub-id pub-id-type="pmcid">PMC7901269</pub-id></mixed-citation></ref><ref id="cit0111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>VanBlargan</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Bloyet</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Rothlauf</surname><given-names>PW</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Stumpf</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Errico</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Theel</surname><given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Ellebedy</surname><given-names>A</given-names></string-name>, et al</person-group>. <article-title>Landscape analysis of escape variants identifies SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization</article-title>. <source>bioRxiv</source>. <year>2020Nov 8;2020.11.06.372037</year>. doi:<pub-id pub-id-type="doi">10.1101/2020.11.06.372037</pub-id>.</mixed-citation></ref><ref id="cit0112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weisblum</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Schmidt</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>DaSilva</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Poston</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lorenzi</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Muecksch</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rutkowska</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hoffmann</surname><given-names>-H-H</given-names></string-name>, <string-name name-style="western"><surname>Michailidis</surname><given-names>E</given-names></string-name>, et al</person-group>. <article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title>. <source>Elife</source>. <year>2020</year>:<fpage>9</fpage>. doi:<pub-id pub-id-type="doi">10.7554/eLife.61312</pub-id>.<pub-id pub-id-type="pmcid">PMC7723407</pub-id><pub-id pub-id-type="pmid">33112236</pub-id></mixed-citation></ref><ref id="cit0113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hemida</surname><given-names>MG</given-names></string-name></person-group>. <article-title>The next-generation coronavirus diagnostic techniques with particular emphasis on the SARS-CoV-2</article-title>. <source>J Med Virol</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1002/jmv.26926</pub-id>.<pub-id pub-id-type="pmcid">PMC8207115</pub-id><pub-id pub-id-type="pmid">33751621</pub-id></mixed-citation></ref><ref id="cit0114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Werner</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Moliva</surname><given-names>JI</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Stewart-Jones</surname><given-names>GBE</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Graham</surname><given-names>BS</given-names></string-name>, et al</person-group>. <article-title>mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants</article-title>. <source>bioRxiv</source>. <year>2021 Jan 25;2021.01.25.427948</year>. doi:<pub-id pub-id-type="doi">10.1101/2021.01.25.427948</pub-id>.</mixed-citation></ref><ref id="cit0115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Felgenhauer</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Schoen</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gad</surname><given-names>HH</given-names></string-name>, <string-name name-style="western"><surname>Hartmann</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Schaubmar</surname><given-names>AR</given-names></string-name>, <string-name name-style="western"><surname>Failing</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Drosten</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Weber</surname><given-names>F</given-names></string-name></person-group>. <article-title>Inhibition of SARS-CoV-2 by type I and type III interferons</article-title>. <source>J Biol Chem</source>. <year>2020</year>;<volume>295</volume>:<fpage>13958</fpage>&#8211;<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.AC120.013788</pub-id>.<pub-id pub-id-type="pmid">32587093</pub-id><pub-id pub-id-type="pmcid">PMC7549028</pub-id></mixed-citation></ref><ref id="cit0116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yu</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Chaturvedi</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Braunstein</surname><given-names>EM</given-names></string-name>, <string-name name-style="western"><surname>Brodsky</surname><given-names>RA</given-names></string-name></person-group>. <article-title>Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition</article-title>. <source>Blood</source>. <year>2020</year>;<volume>136</volume>:<fpage>2080</fpage>&#8211;<lpage>89</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood.2020008248</pub-id>.<pub-id pub-id-type="pmid">32877502</pub-id><pub-id pub-id-type="pmcid">PMC7596849</pub-id></mixed-citation></ref><ref id="cit0117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Volpatti</surname><given-names>LR</given-names></string-name>, <string-name name-style="western"><surname>Wallace</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Raczy</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Alpar</surname><given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>Briquez</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Mitrousis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Marchell</surname><given-names>TM</given-names></string-name>, et al</person-group>. <article-title>Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunity</article-title>. <source>bioRxiv</source>. <year>2021</year>. doi:<pub-id pub-id-type="doi">10.1101/2021.04.08.438884</pub-id>.<pub-id pub-id-type="pmcid">PMC8315245</pub-id><pub-id pub-id-type="pmid">34466656</pub-id></mixed-citation></ref><ref id="cit0118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Jiang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>An</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, et al</person-group>. <article-title>Clinical and pathological investigation of patients with severe COVID-19</article-title>. <source>JCI Insight</source>. <year>2020Jun 18;5(12):e138070</year>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.138070</pub-id>.<pub-id pub-id-type="pmcid">PMC7406259</pub-id><pub-id pub-id-type="pmid">32427582</pub-id></mixed-citation></ref><ref id="cit0119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shirato</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kizaki</surname><given-names>T</given-names></string-name></person-group>. <article-title>SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages</article-title>. <source>Heliyon</source>. <year>2021</year>;<volume>7</volume>:<fpage>e06187</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06187</pub-id>.<pub-id pub-id-type="pmid">33644468</pub-id><pub-id pub-id-type="pmcid">PMC7887388</pub-id></mixed-citation></ref><ref id="cit0120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Root-Bernstein</surname><given-names>R</given-names></string-name></person-group>. <article-title>Innate receptor activation patterns involving TLR and NLR synergisms in COVID-19, ALI/ARDS and sepsis cytokine storms: a review and model making novel predictions and therapeutic suggestions</article-title>. <source>Int J Mol Sci</source>. <year>2021</year>:<fpage>22</fpage>. doi:<pub-id pub-id-type="doi">10.3390/ijms22042108</pub-id>.<pub-id pub-id-type="pmcid">PMC7924650</pub-id><pub-id pub-id-type="pmid">33672738</pub-id></mixed-citation></ref><ref id="cit0121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zuin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rigatelli</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Zuliani</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Roncon</surname><given-names>L</given-names></string-name></person-group>. <article-title>Fatigue as long-term consequence of ARDS in COVID-19 patients</article-title>. <source>Anaesth Crit Care Pain Med</source>. <year>2021</year>;<volume>40</volume>:<fpage>100787</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.accpm.2020.10.016</pub-id>.<pub-id pub-id-type="pmid">33249175</pub-id><pub-id pub-id-type="pmcid">PMC7690302</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>